Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 1 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
   
Clinical Investigation Plan  
Clinical Investigation Plan/Study Title  Evaluati on of BIS ™ and Levels of Sedat ion with 
Common Inhalational Anesthetics in Healthy 
Volunte ers (OLIVER)  
Clinical Investigation Plan Identifier  MDT19053OLIVER  
Study Product Name  [CONTACT_231032]™ Complete Monitoring System  
Sponsor/Local Sponsor  Medtronic,  
Medical Surgical Portfolio  
Patient Monitoring OU   
[ADDRESS_278125]  know  that it is 
confidential  and that it may  not be further  disclosed  by [CONTACT_476].  
  

Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 2 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  Table of Contents  
 
Table of Contents  ................................ ................................ ................................ ......................  2 
Table of Tables  ................................ ................................ ................................ ..........................  5 
Table of Figures  ................................ ................................ ................................ .........................  6 
2. Glossary  ................................ ................................ ................................ ..............................  6 
3. Synopsis  ................................ ................................ ................................ .............................  9 
4. Introduction  ................................ ................................ ................................ .....................  19 
4.1. Background  ................................ ................................ ................................ ...........................  19 
Basics of Anesthesia & Anesthetics  .................................................................................................... 19 
EEG Monitoring in Anesthesia  ............................................................................................................ 20 
Clinical Summary  .................................................................................................................................  21 
Purpose  ................................ ................................ ................................ ................................ ........  21 
5. Objectives  ................................ ................................ ................................ ........................  22 
5.1. Objectives  ................................ ................................ ................................ .............................  22 
Primary Objective(s)  ............................................................................................................................ 22 
Secondary Objective(s)  ....................................................................................................................... [ADDRESS_278126] Description ................................ ................................ ................................ ..........  25 
7.1. General  ................................ ................................ ................................ ................................ . 25 
7.2. Manufacturer  ................................ ................................ ................................ .........................  25 
7.3. Packaging  ................................ ................................ ................................ ..............................  25 
7.4. Intended Population  ................................ ................................ ................................ ...............  25 
BIS™ Com plete Monitoring System Indications for Use  ..................................................................... 26 
7.5. Equipment  ................................ ................................ ................................ .............................  26 
BIS™ Complete Monitoring System  .................................................................................................... 26 
BISx4™  ................................................................................................................................................. 27 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 3 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  Patient Interface Cable  ....................................................................................................................... 27 
BIS™ Bilateral Sensor  .......................................................................................................................... 28 
Other Equipment  ................................................................................................................................ 28 
Site’s Equipment/Supplies  .................................................................................................................. [ADDRESS_278127] Accountability  ................................ ................................ ................................ ...................  29 
8. Study S ite Requirements  ................................ ................................ ................................ . 30 
8.1 Investigator / Investigation Study Site Selection  ................................ ................................ ...... [ADDRESS_278128] Pre -Screening/Screening  ................................ ................................ .......................  [ADDRESS_278129] Consent  ................................ ................................ ................................ ...............  34 
10.4.  Enroll ment -  Visit 1  ................................ ................................ ................................ ...........  35 
10.5.  Execution - Visit 2  ................................ ................................ ................................ ............  36 
Pre-Procedure  ..................................................................................................................................... 36 
Randomization  .................................................................................................................................... 36 
Procedure  ............................................................................................................................................ 37 
10.6.  Follow -up ................................ ................................ ................................ .........................  42 
Phone Call  ........................................................................................................................................... 42 
10.7.  Assessment of Ef ficacy  ................................ ................................ ................................ ..... 42 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278130] Exit, Withdrawal or Discontinuation  ................................ ................................ ....... 44 
11. Risks and Benefits  ................................ ................................ ................................ .........  45 
11.1.  Potential Risks  ................................ ................................ ................................ ..................  45 
11.2.  BIS™ Sensor Risks  ................................ ................................ ................................ ...........  45 
11.3.  BIS™ Monitoring System Risks  ................................ ................................ ..........................  46 
11.4.  XAVANT STIMPOD™ Quantitative NMT Monitor  ................................ ................................ .. 48 
11.5.  Nellcor™ Pulse Oximeter  ................................ ................................ ................................ ... 49 
11.6.  General Anesthesia Risks  ................................ ................................ ................................ .. 50 
11.7.  Potential Benefits  ................................ ................................ ................................ .............  54 
11.8.  Risk-Benefit Rationale  ................................ ................................ ................................ ....... 54 
12. Adverse Events and Device Deficiencies  ................................ ................................ ....... 55 
12.1.  Adverse Events  ................................ ................................ ................................ ................  55 
12.2.  Device Deficiency  ................................ ................................ ................................ .............  55 
12.3.  Processing Updates and Resolution  ................................ ................................ ...................  56 
12.4.  Definitions/Classifications  ................................ ................................ ................................ .. [ADDRESS_278131] Complaint Reporting  ................................ ................................ ................................ .. 60 
13. Data Review Committees  ................................ ................................ ..............................  60 
14. Statistical Design and Methods  ................................ ................................ .....................  61 
14.1.  Sample Size Justification  ................................ ................................ ................................ ... 61 
14.2.  Analysis Populations  ................................ ................................ ................................ .........  61 
14.3.  Statistical Methods  ................................ ................................ ................................ ...........  61 
14.4.  Interim Review  ................................ ................................ ................................ .................  62 
15. Ethics  ................................ ................................ ................................ .............................  62 
15.1.  Statement(s) of Compliance  ................................ ................................ ..............................  62 
16. Study Administration  ................................ ................................ ................................ ..... 63 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278132]  Access to Source Data/Documents  ................................ ................................ ...........  [ADDRESS_278133]  Retention  ................................ ................................ ................................ .............  65 
16.7.1  Investigator Records  .......................................................................................................... 65 
16.7.2  Sponsor Records  ................................................................................................................ 67 
16.8.  Reporting Requirements  ................................ ................................ ................................ ... 67 
Investigator Reports  ............................................................................................................................ 67 
Sponsor Reports  .................................................................................................................................. 68 
16.9.  Publication and Use of Information  ................................ ................................ ....................  68 
16.10.  Suspension or Early Termination  ................................ ................................ .......................  69 
17. References  ................................ ................................ ................................ .....................  70 
18. Appendices  ................................ ................................ ................................ ....................  73 
Appendix A - Modified Observer's Assessment of Alertness/Sedation scale  ................................ ........  73 
19. Version History  ................................ ................................ ................................ ..............  78 
 
Table of Tables  
Table 1: Clinical Data from Literature  .......................................................................................................................... 21 
Table 2 : System product/component information for the [LOCATION_002]  ................................................................... 33 
Table 3 : Schedule of Events  ......................................................................................................................................... 32 
Table 4: Possible Side Effects using Medication  .......................................................................................................... 49 
Table 5: Adverse Event and Device Deficiency Definitions  .......................................................................................... 53 
Table 6: Adverse Event Classification Responsibilities  ................................................................................................ 55 
Table 7: Reporting Requirements  ................................................................................................................................ 56 
Table 8 : Investigator reports applicable for all geographies per Medtronic requirements  ........................................ 65 
 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 6 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  Table of Figures  
Figure 1: BIS™ Range Guidelines; a general association between clinical state and BIS™ values  ............................... 21 
Figure 2: The BIS ™ Complete Monitor ing System. 1 -  Monitor Interface Cable; 2 -  BIS™ Monitor; 3 - BIS™ bilateral 
sensor will be used; 4 - Patient Interface Cable (PIC); 5 - BISx4™ (LoC 4 Channel)  ....................................................... 27 
Figure 3: BISx4 ™ and PIC .  1- Monitor Interface Cable; 2 - Patient Interfa ce Cable; 3 - BISx4 ™ (BIS LoC 4 Channel)  ... 27 
Figur e 4: BIS ™ Bilateral Sensor  .................................................................................................................................... 28 
 
 
2. Glossary  
Term  Definition /Acronyms  
ADE Adverse Device Effect  
AE Adverse Event  
AEAC  Adverse Events Advisory Committee  
ASA American Society of Anesthesiology  
BIS™ Bispectral Index (BIS) technology monitoring uses processed EEG signals to measure sedation 
depth based on the level of consciousness  
BMI Body Mass Index  
bpm  Beats per minute  
CA Competent  Authority  
CBC Complete Blood Count  
CIP Clinical Investigational Plan  
CO [ADDRESS_278134]. C apnograph outputs numeric 
values and waveform s of the fractioned concentration of CO 2 of each breath  
CRF Case Report Form. Forms where the clinical data are collected. eCRF is the electronic version of the 
CRF 
CTA Clinical Trial Agreement  
CV Curriculum Vitae  
DD Device Deviation  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 7 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  Term  Definition /Acronyms  
DMC  Data Monitoring Committee  
DMP  Data Management Plan  
EC Ethics Committee  
ECG Electrocardiogram. A diagnostic tool that measures and records the electrical activity of the heart  
ED Effective dose  
EDC Electronic Data Capture. Electronic  system s where the data are collected through the eCRF (Oracle 
Clinical). May also be referred to as RDC (Remote Data Capture).  
EEG Electroencephalogram  
EMR  Electronic Medical Record. Digital version of a patient’s medical record within a single facility.  
ET End- tidal concentration  
ETDES End- tidal concentration of Desflurane  
ETSEVO End- tidal concentration of Sevoflurane  
EtCO [ADDRESS_278135]  
ISF Investigator Site File. Regulatory binder supplied by [CONTACT_230953] ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 8 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  Term  Definition /Acronyms  
LMA  Laryngeal mask 
LOC Level of consciousness  
MAC  Minimum alveolar concentration  
MOAA/S  Modified Observer's Assessment of Alertness/Sedation  
NSR Non -significant Rsik  
PI [INVESTIGATOR_678]. The person  responsible for overseeing the study and assuring study 
completion in compliance with  applicable regulations.  
PIC Patient Interface Cable  
PK/PD  Pharmacokinetics and pharmacodynamics  
POC  Point of Care  
RA Regulatory Authority  
SpO2  A non-invasive spectroscopic estimate of arterial oxygen saturation measured transcutaneously by 
a pulse oximeter  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SOP Standard Operating Procedures  
TES Tetanic Electrical Stimulation  
TCI Target -controlled infusion  
TIVA  Total Intravenous Anesthesia  
UADE  Unanticipated Adverse Device Effect  
[LOCATION_003]DE  Unanticipated Serious Adverse Device Effect  
  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 9 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  3. Synopsis  
Title  Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalational 
Anesthetics in Healthy Volunte ers (OLIVER)  
Product Name  [CONTACT_231033] ( BIS™ ) Complete Monitoring System  
Sponsor  Medtronic  
Medical Surgical Portfolio  
Patient Monitoring  OU 
[ADDRESS_278136]  
Boulder, CO [ZIP_CODE]   
Indication under 
investigation  Validation of the BIS™ index, one of the Complete Monitor output parameters, 
as an aid in monitoring the effects of desflurane , isoflurane and sevoflurane 
with balanced anesthetic techniques for adult patients.  
Investigation 
Purpose  To investigate the relationship between BIS ™ and inhaled anesthetics across a 
wide range of anesthetic concentration and hypnotic states , and to provide 
evidence to support BIS ™ performance in use with isoflurane , sevoflurane and 
desflurane in combination  with opi[INVESTIGATOR_2438].  
Product Status  BIS™ is commercially available in the [LOCATION_002]  
Primary Objective  To determine BIS 50 (BIS™ value at which 50% of patients will be unresponsive at 
a given drug concentration)  
Secondary 
Objective (s) To determine BIS 95 (BIS™ value at which 95% of patients will be unresponsive at 
a given drug concentration)  
To determine Prediction Probability (P K) for correctly predicting if the subject 
was responsive or unresponsive.  
Study Design  This is a prospective , randomized stu dy to collect data to evaluate the 
relationship between BIS ™ and inhaled anesthetics  without and  with opi[INVESTIGATOR_2438] . 
Five groups of anesthetics regimens will be studied as follow:  
1. Sevoflurane alone  
2. Sevoflurane with Remifentanil  
3. Sevoflurane with Fentanyl   
4. Desflurane alone  
5. Isoflurane alone  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 10 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  Healthy Volunteer  Subjects  will be randomized  to one of the anesthetic 
regimen  groups . The BIS ™ bilateral sensor will be placed on the subject’s 
forehead to study the effects of these drugs on the brain. Each subject will be 
given a  sequence of  dose range s of the target drug to achieve targeted drug 
concentration.  
If required, a training group, comprising of the first [ADDRESS_278137], 
randomization will proceed based on the Sponsor’s assessment of data quality.  
The Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale will 
be used at each steady -state step  to measure the level of alertness in sedated 
subjects . Subjects will then be assessed using a Pi[INVESTIGATOR_230881] a 
standardize d set of pi[INVESTIGATOR_499] . Tetanic Electrical Stimulation (TES) will be used 
once the patient i s unresponsive to painful  stimuli (e.g., MOAA/S = 0, BIS ™ < 
40).   
TES will then be initiated once the subject reaches a MOAA/S = 0 , BIS™ value <  
[ADDRESS_278138] 
does not purposefully (i.e. attempting to push the stimulus away) respond, the stimulation will increase to 30mA, 50Hz for 1 -5 seconds, then 40mA, 50  hertz 
(Hz) for [ADDRESS_278139] will be considered a non -purposeful 
responder (i.e. exhibiting a reflex w ithdrawal, facial grimace, or groan)  and their 
response such as wit hdrawal of extremity, facial grimace or other will be 
recorded along with the BIS™ value prior to stimulation, at the end of all 
stimulation and approximately [ADDRESS_278140] does respond t o any of the stimulations 
with a  purposeful response, the TES will be ended, the response will be noted 
and the BIS™ value will be recorded at the time TES is ended and at 
approximately [ADDRESS_278141] is conscious.  
Randomization  Once enrolled, subjects will be equally randomized to one of the anesthetic 
regimen groups.  
Sample Size  A two -stage adaptive design is used in this study. For each regimen group, 10 
subjects will be enrolled in stage 1, and upon evaluation, up to 20 additional 
subjects will be enrolled in stage 2. With 5 regimen groups, a maximum of 150 
subjects will be enro lled. Based on the dose -response equation ( logistic model)  
with an allowable error of ± 15% for BIS 50 and a coefficient of variation of 25% 
at the alpha level of 0.05, the sample size will provide sufficient power (>80%) 
to evaluate the performance of anes thetic agents.   
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278142]’s participation is approximately [ADDRESS_278143] will be contact[CONTACT_30781] 48 hours of the study participation.   
Planned number of 
sites  Three to four investigational sites in the US  
Inclusion/Exclusion 
Criteria  Inclusion Criteria:  
1) Healthy ( American Society of Anesthesiology ( ASA)  physical status 1), 
male or female subjects between the ages of 18 to 60 years;  
2) Completion of a health screening for a medical history by a licensed 
physician, nurse practitioner or physician assistant;  
3) Vital signs must be within the following ranges to be included: Vital 
signs measured sitting after [ADDRESS_278144]; heart rate: 45 -90 beats per 
minute ( bpm ); systolic blood pressure: 110 -140; diastolic blood 
pressure: 50 -90. Out -of-range vital signs may be repeated once. [Pre -
dose vital signs will be assessed by [CONTACT_079] [INVESTIGATOR_126985] (e.g., a medically qualified sub -investigator) before study drug 
administration. The Principal Investigator (PI) or designee will verify the 
eligibility of each subject with out -of-range vital signs and document 
approval before dosing].  
Exclusion Criteria:  
1) Has severe contact [CONTACT_230954] a reaction to standard 
adhesive materials found in pulse oximetry sensors, electrocardiogram 
(ECG)  electrodes, respi[INVESTIGATOR_230882], or other medical 
sensors [self -reported];   
2) Known neurological disorder (e.g., epi[INVESTIGATOR_002], the presence o f a brain 
tumor, a history of brain surgery, hydrocephalic disorders, depression 
needing treatment with anti -depressive drugs, a history of brain 
trauma) [self- reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
3) Known cardiovascular disease (e.g., hypertension, co ronary artery 
disease, prior acute myocardial infarction, any valvular and/or 
myocardial disease involving a decrease in ejection fraction, 
arrhythmias, which are either symptomatic or require continuous 
medication/ pacemaker/ automatic internal cardiovert er defibrillator) , 
current implanted pacemaker or automatic internal cardioverter 
defibrillator [self -reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 12 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  4) Has a clinically significant abnormal finding on medical history, physical 
examination, clinical laboratory te sts, or ECG at the screening [self -
reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
5) Use of psychoactive medication  within the past 60 days  (e.g., 
benzodiazepi[INVESTIGATOR_1651], antiepi[INVESTIGATOR_006], Parkinson ’s medication, anti -
depressant drugs, opi[INVESTIGATOR_2438]) [self -reported and as sessment by [CONTACT_976] [INVESTIGATOR_42550]];  
6) Subjects with known gastric diseases [self -reported and assessment by 
[CONTACT_976] [INVESTIGATOR_9232]];  
7) Has a positive urine cotinine test or urine drug screen or oral ethanol 
test [ point of care ( POC ) testing];  
8) Known history of allergic or adverse response to drugs to be 
administered [self- reported];   
9) Known history of complications relating to previous general anesthesia 
or conscious sedation [self -reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
10) Known history of malignant hyperthermia [self -reported and assessment 
by [CONTACT_976] [INVESTIGATOR_9232]];  
11) Has a room air saturation less than 95% by [CONTACT_406] [measurement 
by [CONTACT_976] [INVESTIGATOR_9232]];  
12) Has a clinically significant abnormal pulmonary function test via 
spi[INVESTIGATOR_038] [assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
13) Pregnant or lactating women [assessed by [CONTACT_230955]- reported];  
14) Subjects with tattooed skin specific to the sensor placement areas 
(forehead, fingers, chest) [self- reported and assessment by [CONTACT_976] [INVESTIGATOR_42550]];  
15) The subject must not take any  prescription medication, except female 
hormonal contraceptives or hormone replacement therapy, from 14 
days before the dosing until the end -of-study visit without evaluation 
and approval by [CONTACT_737]. Subjects who participated in a 
previous clinical trial who received a required Food and Drug 
Administration ( FDA) approved concomitant medication, for example, 
naltrexone, but were not randomized may be considered for 
participation in this study if they meet the washout requirement 
[assessment by [CONTACT_976] [INVESTIGATOR_230883]].  
Study Procedures 
and Assessments  Pre-Screening:  
• Online or phone call pre -screening 
Enrollment Visit (Visit 1):  
• Informed Consent Process  
• Medical Screening:  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 13 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  o Medical History  
o Physical Examination  
o ASA physical assessment  
o Electrocardiogram (ECG)  
o Complete Blood Count (CBC)  
o Urine Testing for presence of:  
o Cotinine (nicotine metabolite)  
o Pregnancy - for subjects able to bear children  
 
The subject will be instructed not to consume beverages and foods containing 
alcohol, grapefruit , or caffeine/xanthine from [ADDRESS_278145].  
Study enrollment is accomplished  by [CONTACT_230956]/exclusion criteria and health screening 
evaluation. Subjects who sign informed consent, but are not enrolled, are 
considered screen  failures . 
Execution Visit (Visit 2):  
Prior to Randomization:  
• Inclusion/Exclusion Assessment  
• Vital Signs  
• Urine Testing for presence of:  
• Cotinine (nicotine metabolite)  
• Pregnancy - for subjects of childbearing potential  
• Alcohol Breathalyzer  
 
Randomization  
Procedure:  
• BIS™ sensor application and connection to BIS ™ Monitor  
• TES sensor application to the calf with a stimulation of 5 mA, 5Hz for 1 -5 
seconds or per device Instructions for Use ( IFU) provided to ensure 
proper application  
• Safety Management  
• Intravenous Catheter Insertion for fluid and drug administration  
• Blood pressure monitoring  
• Electroencephalogram ( EEG), Pulse Oximeter for  saturation pulse oxygen 
(SpO 2), Capnography (or an other system) for respi[INVESTIGATOR_697], and  end-
tidal carbon dioxide ( EtCO 2) 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 14 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • BIS™, Pi[INVESTIGATOR_230884]  (for the sevoflurane, sevoflurane with 
remifentanil and sevoflurane with fentanyl  groups ), Modified Observer's 
Assessment of Alertness/Sedation ( MOAA/S ) Assessments  
TES assessment as described above . A clinician will be monitoring respi[INVESTIGATOR_230885]. The respi[INVESTIGATOR_230886], adequate oxygenation (SpO 2 > 92%), and carbon  dioxide 
(CO 2) homeostasis throughout the study. As needed for airway support, the 
anesthesiologist may gently lift chin or jaw thrust (with or without manually 
assisted breathing), insertion of an airway device (oropharyngeal airway or 
laryngeal mask airw ay) and/or intermittent positive pressure ventilation (IPPV). 
Mask or nasal cannula will be used for supplemental oxygen ( O2) delivery. Any 
study procedures may be discontinued for the subject’s safety.   
The opi[INVESTIGATOR_2438] (remifentanil and fentanyl) will be administered via the target -
controlled infusion (TCI) pump using either the preprogrammed pump protocols or computer -controlled program, e.g., Total Intravenous Anesthesia 
(TIVA ) Trainer, or another computer- controlled program, to ensure that the 
targeted effect- site concentration of a drug is reached and maintained at each 
drug concentration plateau. Remifentanil and Fentanyl diluted to a single 
concentration of 50 µg/ml will be used for this study. The infus ion rate between 
0 and 1200 ml/hr will be used to achieve a target effect -site concentration of 
remifentanil and fentanyl. For remifentanil, Minto 
pharmacokinetics/pharmacodynamics ( PK/PD)  model will be used. [1]  The 
kinetic model for fentanyl will not be weight -adjusted .[2]  
Inhalation anesthetic drugs will be administered via a tight -fitting face mask or 
a laryngeal mask (LMA). Volunteers will be connected to a circular breathing 
system of an anesthesia machine. After the volunteer loses responsiveness, LMA may be inserted as needed to facilitate airway control at deeper levels  of 
anesthesia.  Once emergence is started, LMA should be removed at the earliest 
point while ensuring subject safety . Inhalation agents will be administered with 
O
2 to maintain saturation of greater than 90%.  
Lidocaine can be administered per Investigator discretion as a bolus over [ADDRESS_278146]’s comfort.  
Phenylephrine  may  be used pro phylactically on all subjects at a concentration 
of 100 mcg/mL  for the prevention  of hypotension as a result of inhaled 
anesthetics . 
Antiemetic / anti -nausea medication (i.e. Ondansetron ) may be used 
prophylactically on all subjects for the prevention of nausea and vomiting at the investigator’s discretion.  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278147] 12 minutes before starting any regimen.  
Sevoflurane Group, following approximately 2 minutes of baseline 
measurement, sevoflurane will be administered via a tight -face mask in steps to 
achiev e a loss of consciousness by [CONTACT_230957] -tidal concentration of 
sevoflurane (ET SEVO). Targeted concentration for ET SEVO are 0.2, 0.5, 0.7, 1,  2, 3, 
4, 5% or higher until  a BIS™ value not less than 30 is reached or per 
Investigator’s discretion. The BIS™ value should  be taken to at least 40,  but not 
intentionally below 30.  The equilibration time for each targeted concentration 
will be approximately  12 minutes to maintain a constant ET SEVO. The BIS ™ value , 
MOAA/S score  and Pi[INVESTIGATOR_230887].  TES will then be initiated once the subject reaches a MOAA/S = 
0, BIS™ value <  [ADDRESS_278148] concentration of anesthesia anticipated . The 
BIS™ value will be recorded at the immediate end of the assessment and 
approximately [ADDRESS_278149] -site targeted co ncentration of 
remifentanil of 4 ng/ml, an initial IV bolus of remifentanil will be given followed 
by [CONTACT_230958]. Approximately within [ADDRESS_278150] -site concentration of 
remifentanil of 4 ng/ml.  
Sevoflurane will be administered via a tight -face mask in steps to achieve a loss 
of consciousness by [CONTACT_230957] -tidal concentration of sevoflurane 
(ET SEVO). Targeted concentration for ET SEVO are 0.2, 0.5, 0.7, 1,  2, 3, 4, 5% or 
higher until a BIS™ value not less than 30 is reached or per Investigator’s 
discretion. The BIS™ value should be taken to at least 40,  but not intentionally 
below 30.  
The equilibration time for each targeted plateau will be approximately  12 
minutes. The BIS ™ value, MOAA/S score and Pi[INVESTIGATOR_1103] R ecall test  will be assessed  
when the patient is awake  and prior to the induction of any anesthetic  and at 
each  ETSEVO concentration s with the exception of the Pi[INVESTIGATOR_230888], which 
will just be completed at the first three steps . TES will then be initiated once 
the subject reaches a MOAA/S = 0, BIS™ value <  [ADDRESS_278151] concentration 
of anesthesia anticipated . The BIS ™ value  will be recorded at the immediate 
end of the assessment  and approximately [ADDRESS_278152] -site targeted concentration of fentanyl of 2 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 16 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  ng/mL, an initial IV bolus of fentanyl will be given followed by [CONTACT_230959]. Approximately within [ADDRESS_278153]- site concentration of fentanyl of 2 ng/ml.  
Sevoflurane will be administered via a tight -face mask in steps to achieve a loss 
of consciousness by [CONTACT_230957] -tidal concentration of sevoflurane 
(ET SEVO). Targe ted concentration for ET SEVO are 0.2, 0.5, 0.7, 1,  2, 3, 4, 5% or 
higher until a BIS™ value not less than 30 is reached or per Investigator’s 
discretion. The BIS™ value should be taken to at least 40, but not intentionally  
below 30.   
The equilibration tim e for each targeted plateau will be at least 12 minutes.  
The BIS ™ value, MOAA/S score and Pi[INVESTIGATOR_230889], which will 
just be completed at the first three steps . TES will then be initiated once the 
subject reaches a MOAA/S = 0, BIS™ value <[ADDRESS_278154] concentration of 
anesthesia anticipated . The BIS ™ value w ill be recorded at the time of subject’s 
response and approximately 2 minutes following the TES assessment.   ETSEVO is 
decreased by [CONTACT_230960].  
The cardiac output will be monitored, and subjects could be discontinued pe r 
PIs discretion . The respi[INVESTIGATOR_135890] 4 breaths/minute or less will be 
considered evidence of fentanyl -induced respi[INVESTIGATOR_2341], and fentanyl 
will be discontinued.  
Desflurane Group, Due to desflurane being a volatile agent and not well 
tolerated as an induction agent,  an initial intravenous IV bolus of 1% propofol  
provided at 2mg/kg,  with supplemental boluses given at the investigator ’s 
discretion , in order to achieve LMA insertion . Propofol  will be administered  0-
15 minutes prior to des flurane. Desflurane will then be administered  via a tight -
face  mask  or LMA  at the targeted end -tidal concentration  of desflurane  (ET DES) 
of 2, 5, 7, 8, 9, 10 %, or higher until a BIS™ value not less than 30 is reached or 
per Investigator’s discretion. The BIS™ value should  be taken to at least 40, not 
intentionally below 30.   
The equilibration time for each targeted plateau will be  approximately  12 
minutes.  The BIS ™ value  and MOAA/S score will be assessed when the patient 
is awake and at the different ET DES concentrations. TES will then be initiated 
once the subject reaches a MOAA/S  = 0, BIS™ value < [ADDRESS_278155] 
concentration of anesthesia anticipated . The BIS ™ value will be recorded at the  
immediate end of the assessment and approximate ly 2 minutes following the 
TES assessment.   
The BIS ™ value will be correlated with desflurane ET DES concentration.  LMA 
should be removed at the highest level of sedation while maintaining subject’s 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 17 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  safety in order to allow for a gradual emergence from anesthesia.  ETDES is 
decreased by [CONTACT_230960].  
Isoflurane Group: Due to isoflurane b eing a volatile agent and not well 
tolerated as an induction agent, an initial IV bolus of 1% propofol provided at 
2mg/kg, with supplemental boluses given at the investigators discretion in order to achieve LMA insertion, will be administered  0-15 minutes prior to 
isoflurane.  Isoflurane  will be administered via a tight -face mask  or LMA  in steps 
to achieve a loss of consciousness (MOAA/S of 0  or 1) by [CONTACT_230957] -
tidal concentration of Isoflurane  (ET
ISO). Targeted concentration for ET ISO are 
0.2, 0.5, 0.7, 1, 1.5 % or higher until a BIS™ value not less than 30 is reached or 
per Investigator’s discretion. The BIS™ value should not  be taken to at least 40, 
not intentionally be taken below 30.  .  
The equilibration time for each targeted concentration will be approximately 12 
minutes to maintain a constant ET ISO. The BIS ™ value  and MOAA/S score will be 
assessed when the patient is awake and at each  ETISO concentrations. TES will 
then be initiated once the subject reaches a MOAA/S 0, BIS™ value < [ADDRESS_278156] concentration of anesthesia anticipated . The BIS ™ value will be 
recorded at the immediate end of the assessment  and approximately 2 minutes 
following the TES assessment.  
The BIS™ value will be correlated with the isoflurane ET ISO concentration.   LMA 
should be removed at the highest level of sedation  while maintaining subject’s 
safety in order to allow for a gradual emergence from anesthesia. ETISO is 
decreased by [CONTACT_230960].  
The start time of an y drug infusion , target effect- site concentrations, infusion 
rate, the start  and end  time of the assessment including BIS ™ value prior to 
MOAA/S assessment , Pi[INVESTIGATOR_230890] (eCRFs). Any adjus tments to the infusion rate and 
time of adjustment will be recorded, and any changes to subject management during the procedure will be noted on the eCRFs.  
Also, the device data (raw signals), including Heart Rate, Blood Pressure, Respi[INVESTIGATOR_26452], EtCO
2, SpO 2, BIS™, TCI will be recorded in real- time during the 
procedure and files will be provided to Medtronic by [CONTACT_779].  The instructions 
on the secure data transfer will be provided by [CONTACT_13735].  
Each subject will be contact[CONTACT_30781] [ADDRESS_278157] a setting that is fully 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 18 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  equipped for the monitoring and support of the respi[INVESTIGATOR_230891]. Subjects will be continuously m onitored throughout the study.  
Subjects will be monitored for Adverse Events  (AE) , Serious Adverse Events  
(SAE), and Device -Related Adverse Events from the BIS ™ sensor application 
throughout the study and through the follow -up phone call.  
 Statistics  Data will be analyzed by [CONTACT_13760]. Any changes in statistical 
methods will be detailed  in the Clinical Study Report.  
Standard demographic information and baseline characteristics will be 
summarized using descriptive statistics. For safety assessments, AEs will be 
summarized using frequency counts and percentages. Descriptive statistics will 
be provided by [CONTACT_230961] .  
The primary effectiveness analysis will be based on all evaluable data collected 
from the left side of the brain to reflect the typi[INVESTIGATOR_230892]. The BIS ™ index value collected from the right side of th e brain will 
be used for research.  
All randomized subjects will be included in the analysis. For those subjects who 
do not complete a follow -up call, the analysis will include all data up to the last 
collected point or follow -up call. Subjects who complete d the procedure phase 
will not be replaced. If the subject discontinues before randomization or during 
the procedure phase, she/he will be replaced.  
Any subject who responds to any verbal command with MOAA/S assessment score of  2, 3, 4, and 5 will be considered as responsive. Subjects with MOAA/S 
assessment scores of 0  and 1 will be considered unresponsive.  
The data will be analyzed for each regimen. The logistic  model ( simplified E
max  
model ) will be used to analyze the relationship between the BIS ™ index and loss 
of responsiveness through the probability of response curves. The values of BIS™, at which 50% (BIS
50) and 95% (BIS 95) of subjects are unresponsive, and 
their 95% confidence intervals will be derived. The systematic variance 
between groups will be  evaluated. The Prediction Probability score (P K) for 
correctly predicting if the subject was responsive or unresponsive will be 
assessed.   
An interim review  will be performed by [CONTACT_230962] 1 , when all ( 50 
subjects with  10 subjects per group) have completed the evaluation. Both the 
primary and secondary objectives will be evaluated during the interim review . 
One or more groups may be dropped upon interim results for safety concern 
(unacceptable safety events per clinical judgment) .  
 
  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 19 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  4. Introduction  
1.  
2.  
3.  
4.  
4.1. Background  
4.1.2  Basics of Anesthesia & Anesthetics  
General anesthesia (GA) is a reversible state of controlled unconsciousness that is achieved with drugs 
that prevent awareness, pain, recall, distress, and movement in patients during surgery. General 
anesthesia is performed by [CONTACT_230963], generally anesthesiologists and nurse anesthetists, with extensive education and training in the physiology, pharmacology, techniques, and risks involved.  
 Two critical components of general anesthesia are hypnosis and analgesia. Maintaining an adequate level of anesthesia depth is critical to the attenuation of these responses. The hypnotic component can be 
defined as the probability of tolerance to non -painful stimulus, e.g., name -calling, shaking, and shouting. 
The analgesic component may be considered as th e probability of tolerance to a painful stimulus. 
Tolerance is the absence of a response, either a somatic response ( e.g., movement, sweating, eye -
opening) or a hemodynamic response (increase in heart rate or blood pressure). When the state of general 
anes thesia is inadequate for the level of nociceptive stimulation from surgery, the heart rate and blood 
pressure can increase dramatically, alerting the anesthesiology provider to the possibility of increased 
nociception and arousal. Higher doses of an anesth etic are necessary to prevent reactions to more intense 
surgical stimuli. This fact has suggested that different states of anesthesia fall along a continuum of depth, 
with deeper anesthesia eliminating reactions to stronger stimuli. Thus, it’s vital that the anesthesiologist 
know when a patient has reached a depth of anesthesia commensurate with an impending stimulus. 
Superficial or deep depth levels can be disastrous in both the short and long run when a patient expects a surgical procedure to be safe and painless, assured that throughout the procedure, they are asleep, 
without any perception or memory during that period. Intravenous anesthetics, including propofol, 
barbiturates, and benzodiazepi[INVESTIGATOR_1651], produce a concentration -dependent reduction in wakefulnes s 
ultimately leading to complete loss of consciousness. The effective dose
 (ED 50) of intravenous anesthetics 
for obtaining general anesthesia is calculated as the effect -site concentration at which [ADDRESS_278158] a designation fo r standardizing each agent’s concentration/effect relationship. 
The minimum alveolar concentration (MAC) is the concentration of volatile anesthetic that prevents 
movement in response to a standard skin incision in 50% of patients.  Despi[INVESTIGATOR_230893], most anesthetic agents appear to cause unconsciousness by [CONTACT_24096], directly or indirectly, 
a posterior lateral corticothalamic complex centered around the inferior parietal lobe, and perhaps a 
medial cortical core of the brain. [3]  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278159] known about changes in the electroencephalogram (EEG) that are  
produced by [CONTACT_167201]. [4] Many of the changes that occur in the brain with changes in anesthetic 
states can be readily observed in unprocessed EEG recordings.  Different behavioral and 
neurophysiological states induced by [CONTACT_230964].  The 
earliest use of the EEG in anesthesia tested the effects of barbiturates, eventually leading to the 
recognition of particular sequential effects shown  in Figure  1. [5, 6]  The first changes induced by 
[CONTACT_230965] 20 -30 Hz (initial rapid response) w aves, followed by [CONTACT_230966] [ADDRESS_278160] as the initial rapid response yields to the slower 
oscillations . Spi[INVESTIGATOR_230894] 5 -12 Hz become prominent , and in turn , decline as the EEG develops large 
polymorphic waves of 1 -3 Hz. When this slow polymorphic activity becomes dominant, the patient 
tolerates skin incision. At still higher concentrations of barbiturates, the EEG displays periods of suppression, each termina ting with “burst” of renewed activity , which contains high -frequency 
components. The burst gradually subsides as it leads into the next epi[INVESTIGATOR_230895]. This 
combination of alternating phases of high -amplitude and low -amplitude periods is called “bu rst 
suppression .”  
 
Monitoring the depth of anesthesia could prevent intraoperative awareness and help to ensure that an 
exact dose of anesthetic drugs is given. The lightness of anesthesia can result in the recall of events that 
happen in the operation room. Anesthesia that is too deep could cause hemodynamic disturbances 
necessitating the use of vasoconstrictor agents, which constrict blood vessels to maintain normal blood 
pressure and cardiac output.  Overly deep anesthesia can also result in respi[INVESTIGATOR_230896] g 
respi[INVESTIGATOR_230897] [7] . There is no objective scale that measures “too light” or  “too 
deep” anesthesia. Bispectral Index (BIS) technology monitoring measure s sedation depth based on 
changes in EEG  signals and allows anesthesia providers to titrate general anesthesia to achieve the  desired 
LOC on the brain [7, 8] . The BIS™ technology  consists of a sensor placed on the patient’s forehead to 
measure  the electrical signals from the cerebral cortex ( the EEG ), a digital signal converter  to digitize the 
EEG, and derive the necessary processed EEG parameters , and a monitor  to display the resultant BIS and 
EEG sig nal. BIS ™ values quantify changes in the electrophysiologic state of the brain during anesthesia. 
BIS™ is a continuous ly processed EEG parameter that correlates to the patient’s level of hypnosis, where 
100 = awake and 0 = isoelectric  EEG. The BIS™  paramet er was designed to correlate with “hypnotic” 
clinical endpoints (sedation, lack of awareness, and memory) and to track changes in the effects of 
anesthetics on the brain.  Overall, a BIS ™ value below 60 is associated with a low probability of response 
to co mmands. [5, 9]  Figure 1  reflects a general association between clinical state and BIS ™ values. Ranges 
are based on results from a multi- center study [8]  of the BIS ™ system involving the administration of 
specific anesthetic agents. BIS ™ values and ranges assume that the EEG is free of artifacts that can affect 
its performance. Titration of anesthetics to the BIS™ range should be dependent upon the individual goals 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 21 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  established for each patient. These goals and associated BIS ™ ranges may vary over time and in the 
context of patient status and treatment plan.  
 
 
Figure 1: BIS™ Range Guidelines ; a general association between clinical state and BIS values  
4.1.2  Clinical Summary  
The BIS ™ system has been on the market for approximately 25  years, and there is a large amount of clinical 
data available to as sess the performance and safety of the device.  Table 1  summarizes overall clinical 
experience regarding the performance and safety of the BIS ™ system in the published clinical literature  
carried out from May 2013 to September 2018. The safety clinical literature reviews accounted for 7,627 
patients and performance data for 43,247 patients . The patient populations included in these studies 
varied  between infants, pediatrics, adults, obese adults, and the elderly.  
 
Table 1: Clinical Data from  Literature  
Performance Data  Safety Data  
Number of Publications  Number of Patients  Number of Publications  Number of Patients  
32 publications addressing 
performance [10-41] 43,247  11 publications with safety 
data [11, 14, 20, 26, 27, 29, 
35-37, 42, 43]  7,627  
 
The c linical literature  review  did not identify any new risks/side effects or safety concerns for the target 
device and its intended indications. The data form published clinical studies included in safety assessment , 
Table 1, did not  reveal any new complications directly related to the use of the devices . 
 
4.2. Purpose  

Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 22 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  To investigate the relationship between BIS ™ and inhaled anesthetics across a wide range of anesthetic 
concentration and hypnotic states, and to provide evidence to support BIS ™ performance in use with 
sevoflurane , isoflurane and desflurane in combination with opi[INVESTIGATOR_2438] . 
5. Objectives  
5.  
5.1. Objectives  
Primary Objective(s)   
To determine BIS 50 (BIS™ value at which 50% of patients will be unresponsive at a given drug 
concentration)  
Secondary Objective(s)  
To determine BIS 95 (BIS™  value at which 9 5% of patients will be unresponsive at a given drug 
concentration)  
To determine Prediction Probability (P K) for correctly predicting if the subject was responsive or 
unresponsive.  
6. Study Design  
This is a prospective, randomized study to collect data to ev aluate the relationship between BIS ™ and 
inhaled anesthetics without and with opi[INVESTIGATOR_2438] . Five groups of anesthetic regimens will be studied as follow:  
1. Sevoflurane alone  
2. Sevoflurane with Remifentanil  
3. Sevoflurane with Fentanyl  
4. Desflurane alone  
5. Isoflurane alone  
Healthy Volunteers  Subjects  will be randomized to an anesthetic  group . The BIS ™ bilateral sensor will be 
placed on the subject’s forehead to study the effects of these drugs on the brain. Each subject will be 
given a sequential dose range of the target drug to achieve targeted drug concentration. At each steady -
state step, and after at least 12 minutes to achieve equilibrium, the Modified Observer's Assessment of 
Alertness/Sedation (MOAA/S) scale will be used to perform sedation/loss of consciousness assessment, 
with the  Pi[INVESTIGATOR_230898], sevoflurane w ith remifentanil and sevoflurane 
with fentanyl regimens to assess the subject’s level of anesthesia awareness, and  Tetanic Electrical 
Stimulation (TES) being used if the patient is unresponsive to tactile stimuli (e.g., MOAA/S  = 0, BIS ™ value 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 23 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  < [ADDRESS_278161] concentration of anesthesia anticipated ). The loss of tactile response will be defined 
according to the MOAA/S score value < 2 (0 -1) and the presence of verbal response at values >2 (2 -5).  
A training group, comprising of the first [ADDRESS_278162], randomization will proceed based on the Sponsor’s assessment of data quality.  
 
Subjects will have the effect of noxious electrical stimulation on the sedation state assessed for each arm  
once they achieve an MOAA/S score =  0, BIS™ value <[ADDRESS_278163] concentration of anesthesia 
anticipated . The baseline BIS ™ value will be record ed, followed by [CONTACT_230967]/S assessment. Once TES is 
initiation, stimulation will start  at 20mA, [ADDRESS_278164] does not 
purposefully (i.e. attempting to push the stimulus away) respond, the stimulation will increase to 30mA,  
50Hz for 1- [ADDRESS_278165] will be considered a non -purposeful responder (i.e. exhibiting 
a reflex withdrawal, facial grimace, or g roan) and their response such as withdrawal of extremity, facial 
grimace or other will be recorded along with the BIS™ value prior to stimulation, at the time of each 
stimulation and approximately [ADDRESS_278166] does r espond to any 
of the stimulations with a purposeful response, the TES will be ended, the response will be noted and the 
BIS™ value will be recorded at the time TES is ended and at approximately 2 minutes following the 
stimulation. LMA should be removed at this point, if allow ed per Investigator’s assessment without risk 
to subject. Anesthesia will then be decreased in the same steps until subject is conscious.  An 
anesthesiologist authorized to administer sedation drugs will be responsible for administering  any 
procedural drugs for the sedation and monitoring of subject safety and physical state. All other personnel 
involved with the safety monitoring of subjects must be trained in and familiar with the management and 
recovery of sedated patients. The study site should utilize  a setting that is fully equipped for the 
monitoring and support of the subject’s respi[INVESTIGATOR_230899] s. Subjects will be 
continuously monitored throughout the study.  
 
A two -stage design is used in this study. For each regimen  group , [ADDRESS_278167] at the end o f stage 1 ( 50 subjects  and 10 subjects per regimen). Both the 
primary and secondary objectives will be evaluated during the interim review , and a particular group (s)  
may be dropped upon interim results  for safety concern s (unacceptable safety events per clinical 
judgment)  (refer to Section 12.)  
 
6.  
6.1. Duration  
Study duration is expected to be up to approximately [ADDRESS_278168]’s 
participation is approximately 6 hours for both enrollment and procedure. The Enrollment Visit should 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278169] will be contact[CONTACT_30781] 48 hours of the study participation.  
    
6.2. Rationale  
This clinical study is designed to capture the performance of BIS ™ with anesthetic agents across a wide 
range of anesthetic concentrations and hypnotic states. The study design  is deemed appropriate in this 
setting  and will provide more information to confirm the performance and safety of the BIS™  monitoring  
system .  
 
The anesthetic regimens  are selected based on cli nical relevance . Inhalational anesthetics (e.g., isoflurane, 
sevoflurane and desflurane) can be used for the induction and maintenance of general anesthesia. Often 
inhaled anesthetics are used alone or in combination with other central nervous system depressants such 
as intravenous sedatives (e.g., propofol) and opi[INVESTIGATOR_2438] (e.g., remifentanil and fentanyl.) During anesthesia,  
isoflurane,  sevoflurane and desflurane can be maintained at end-tidal concentration s of 0.5 – 8% and 2.5  
- 16%, respectively , in co mbination with opi[INVESTIGATOR_2438].  
 
Intravenous (IV) opi[INVESTIGATOR_2438] (e.g., remifentanil and fentanyl) are commonly used to provide analgesia and supplement sedation during general anesthesia. Opi[INVESTIGATOR_230900]. The titration of the opi[INVESTIGATOR_230901] -controlled infusion ( TCI) pumps 
with the benefit that the recovery time from anesthetic doses can be appropriate fo r the individual patient 
and procedure . The TCI pump contains a microprocessor programmed with pharmacokinetic and 
pharmacodynamic models for relevant drugs. The user selects the drug and model to be used by [CONTACT_230968], and the target plasma or ‘brain’ 
(effect -site) concentration, with the pump determining the initial bolus and subsequent infusion rates. 
The commonly used adult model remifentanil is Minto. F or remifentanil, the induction levels of 4 ng/ml 
are commonly used, but the levels generally vary between 2 -8 ng/ml.  [44] For this study, the selected 
target effect- site concentration of remifentanil is 4 ng/ml  to account for subject safety . During surgery , 
the effect- site concentration of fentanyl can vary. The effect- site concentration s of fentanyl between 0.8 
and 1.4 ng/ml are  associated with numerous complaints of postoperative pain,  and concentration s 3.0 
ng/ml and higher are  associated with respi[INVESTIGATOR_230902]. The optimal fentanyl effect -site 
concentration appears to be near 2 ng/ml [45] .   
 A two -stage design will be implemented , given the benefits of patient protection and sample size savings  
for more details , refer to  Section 13.  
 
The de-identified data collected in this study also may be used for future product development.  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278170] Description  
7.  
7.1. General  
The BIS ™ complete monitoring system is a user- configurable patient monitoring system designed to 
monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS ™ 
complete system processes raw EEG signals to produce a single n umber, called the BIS™ index , which 
correlates with the patient's level of hypnosis. A sensor placed on the patient’s head transmits EEG signals 
to the BISx4 ™ unit. The BISx4 ™ unit filters and digitizes the signal, analyzes it for the artifact , and processes 
it using digital signal p rocessing techniques  to derive processed EEG parameters like BIS ™, and finally 
sends the processed data to the monitor for display. The purpose of processing the EEG waveform data 
are to extract characteristic features from the complex signal that the BIS ™ algorithm can utilize to 
ultimately derive BIS ™. 
 
Table 2: System product/component information for the [LOCATION_002]  
Product Number  Component (Manufacturer)  Investigational or Market -released  
185-0151  BIS™ Complete Monitor  (Medtronic)  Market -released  
185-1014 -AMS  BIS™ BISx4 (Medtronic)  Market -released  
186-0107  BIS™ Patient Interface Cable  (Medtronic)  Market -released  
N/A BIS™ Sensor  (Medtronic)  Market -released  
N/A BIS™ Detachable Power Cord  (Medtronic)  Market -released  
 
7.2. Manufacturer  
BIS™ Complete Monitoring System by ([ADDRESS_278171], Mansfield MA) Medtronic Inc.  
 
7.3. Packaging 
The Sponsor is responsible for the packaging and labeling of the devices for shipment to the study site. 
Research conducted for this study will utili ze FDA -cleared (through the 510(k) regulatory process ) devices . 
FDA- cleared devices are being used within the FDA -cleared indications for use and d id not require special 
labeling.  
 
All equipment associated with the clinical study will be identified with v isible markings stating, “For clinical 
trial use only.” Labeling of devices will be provided in accordance with local language requirements.  
 
7.4. Intended Population  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 26 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  BIS™ Complete Monitoring System Indications for Use   
The BIS™ EEG complete monitoring system is intended for use under the direct supervision of a licensed 
healthcare practitioner or by [CONTACT_230969]. The system and its associated parameters 
are intended for use on adult patients within a hospi [INVESTIGATOR_88355], providing patient care to 
monitor the state of the brain by [CONTACT_230970]. The BIS ™ index, one of the Complete 
Monitor output parameters, may be used as an aid in monitoring the effects of Alfentanil, Desflurane,  
Fentanyl, Isoflurane, Midazolam, Nitrous Oxide, Propofol, Remifentanil, Sevoflurane and its usage with 
these anesthetic agents may be associated with a reduction in primary anesthetic use and a reduction in 
emergency and recovery time. Use of the BIS ™ index for monitoring to help guide anesthetic 
administration may be associated with the reduction of incidence of awareness with recall in adults during 
general anesthesia and sedation.  
 
Currently under investigation in this study is the v alidation of the BIS ™ index as an aid in monitoring the 
effects of desflurane , isoflurane , propofol and sevoflurane with balanced anesthetic techniques for adult 
patients.  
7.5. Equipment  
BIS™ Complete Monitoring System  
The BIS ™ Complete Monitor is an easy -to-use microprocessor- based EEG monitor. The BIS ™ Complete 
Monitor reports a BIS value by [CONTACT_230971]’s 
head and performing the computations necessary to produce the BIS  index . The BI S index  is then 
num erically displayed for the clinician’s use. The BIS Complete Monitoring System consists of the following 
components  (Figure 2): 
• BIS™ Complete Monitor  
• BISx4™ (BISx4 ™ will be used in this study)  
• Patient Interface Cable (PIC)  
• BIS™ Sensor  
• Detachable Power Cord  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 27 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
   
Figure 2: The BIS ™ Complete Monitoring System. 1 -  Monitor Interface Cable; 2 -  BIS™ Monitor; 3-  BIS™ bilateral sensor will 
be used; 4 - Patient Interface Cable (PIC); 5-  BISx 4™ (LoC 4 Channel ) 
BISx4™ 
The BISx4 ™ receives, filters, digitizes , and processes patient EEG signals. It is located close to the patient's 
head, where the EEG signal is less subject to interference from other medical equipment. The BISx4 ™ is 
shown in  Figure 3. Its long flexible Monitor Interface Cable connects to the front of the monitor. The 
Patient Interface Cable (PIC) connects the BIS ™ sensor to the BISx 4™. The attachment clip on the BISx 4™ 
is used to secure it in a  convenient location near the patient's head. The BISx4 ™ Module is a variant of the 
BISx™ Module,  and it processes up to four channels of EEG data. In this study, BISx4 ™ Module  will be used 
with Bilateral Sensor.  
 
Figure 3: BISx 4 - 1- Monitor Interface Cable  connects to Monitor ; 2- Patient Interface Cable  connects to BIS sensor ; 3- BISx4 ™ 
(BIS LoC 4 Channel)   
Patient Interface Cable  
Covidien BIS ™ Sensor Patient Interface Cable (PIC) connects the BISx4 ™ to the BIS ™ Sensor , refer to Figure 
3. 
 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 28 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  BIS™ Bilateral Sensor  
The sensor is the single- use component of the BIS ™ Monitoring System and should be replaced after each 
use. BIS™  Bilateral Sensors are designed with a 6 electrode pre -gelled EEG electrode array that is applied 
directly to the patient’s forehead to transmit EEG signals to the BISx4 ™ Module . When the System is 
connected to a BISx4 ™ module and a BIS™ Bilateral Sensor, the monitor displays four channels of EEG.  
 
  
Figure 4: BIS™ Bilateral Sensor  
 
Other Equipment  
Additional equipment such as FDA -cleared Pulse Oximeter (SpO 2 sensors and N600x monitors or other), 
capnography devices and a STIMPOD™  NMS450X nerve stimulator and TOF monitor  may  be provided by 
[CONTACT_42570].  
Site’s Equipment/Supplies  
Sevoflurane, isoflurane, desflurane, propofol, phenylephrine , ondansetron  or other antiemetic / anti -
nausea medication , lidocaine, remifentanil, and fentanyl  will be provided by [CONTACT_779].  The remifentanil and 
fentanyl will be administered using the Total Intravenous Anesthesia (TIVA) method via the target -
controlled infusion (TCI) computer -controlled program, e.g., TIVA Trainer, or another computer-
controlled program . Other monitors will be used per site’s guidance or practice.   
 
7.6. Product Use  
A member of the Medtronic team will set up the BIS™ system at each  participating research site  or will 
guide the site in set up remotely  in order to  ensure all equipment is fully functional. Specific  instructions 
for the Site Investigator and staff  on system set up , use sensor application , and data  transfer will b e 
provided  before  subject enrollment.  
 
 

Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278172] Training Requirements  
Prior to  site activation or subsequent involvement in clinical study activities, Medtronic will provide clinical 
study training relevant and pertinent to the involvement of personnel conducting clinical study activities 
and investigator responsibilities.  Principal Investigators participating in the clinical study and the 
associated clinical study staff will receive training on the device and system (including but not limited to 
device characteristics, storage requirements, warnings, precautions, and contraindicatio ns.)  
It is the responsibility of the Principal Investigator [INVESTIGATOR_230903] ( e.g., Study Coordinators, Study Nurses, Sub -Investigators, etc.) have been 
appropriate ly trained, th eir training documented and included on the Delegation of Authority Log.  
 
7.8. Product Receipt and Tracking  
The investigator or designee will maintain records of devices/products provided by [CONTACT_230972], e.g., device ship pi[INVESTIGATOR_59309]. The following records will be maintained  at 
a minimum  for product delivery, receipt , and tracking at the site: dates, quantities received, lot/serial 
numbers, and expi[INVESTIGATOR_1659], as applicable .  
 
7.9. Product Storage  
Devices/products or products provided by [CONTACT_230973] a secured area. The method of storage shall prevent the use of devices/products for other applications than outlined in this 
Clinical Investigation Plan. In addition, all information for the use, storage, and handling of the 
device/product as indicated in the Instructions for Use (IFU) and User Manual must be taken into account.  
Product Return  
Any devices provided by [CONTACT_230974], and all monitors and accessories should be returned 
to Medtronic and maintain documentation of return. Non -functioning investigational devices must be 
returned to Medtronic as soon as possible for investigation. Instructions for returning the device will be 
provided.  
Product Accountability  
Devices/products will be traced during the clinical study  by [CONTACT_230975]  (or lot numbers) 
assigned  to each device/product. The investigator is responsible for the maintenance of a Product 
Accountability  Log in the Investigator Site File. On this log, the receipt, use, return , and disposal dates of 
the investigational devices/products and subject identification shall be documented. At the end of the 
clinical stu dy, the principal investigator [INVESTIGATOR_230904].  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 30 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  8. Study Site Requirements  
8.1 Investigator / Investigation Study Site Selection  
All investigators managing the subject’s anesthesia must be qualified practitioners and ex perienced in the 
diagnosis and treatment of subjects undergoing anesthesia.  All investigators must be trained in the 
handling of BIS™ Complete Monitoring System.  
The role of the principal investigator [INVESTIGATOR_54365] -to-day conduct of t he clinical 
investigation as well as ensure data integrity and the rights, safety and well- being of the subjects involved 
in the clinical investigation.  
The principal investigator [INVESTIGATOR_67417]:  
• Be qualified by [CONTACT_8640], training, and experience to assume respons ibility for the proper 
conduct of the clinical investigation  
• Be experienced in the field of application and training in the use of BIS™ Complete Monitoring 
System  
• Disclose potential conflicts of interest, including financial, that interfere with the condu ct of 
the clinical investigation or interpretation of results  
• Be able to demonstrate that the proposed investigational study site:  
 Has the required number of eligible subjects needed within the recruitment period  
 Has one or more qualified investigators, a qualified investigational study site team and 
adequate facilities for the foreseen duration of the clinical investigation  
 
Study site personnel training will be completed and documented prior to participation in this study.  
8.2 Study Site Acti vation  
During the activation process (prior to subject enrollment), Medtronic will train study site personnel on 
the clinical investigation plan, on relevant standards and regulations, informed consent, and on data 
collection and reporting tools. If new me mbers join the study site team, they will receive training on the 
applicable study requirements relevant to their role before contributing to the study.  
Prior to performing study related activities, all regulatory requirements shall be fulfilled, including , but 
not limited to the following:  
• Institutional Review Board ( IRB) approval (and voting list, as required by [CONTACT_1769]) of the 
current version of the Clinical Investigational Plan ( CIP) and Informed Consent Form ( ICF)  
• Regulatory Authority ( RA) approval  or notification (as required per local law)  
• Fully executed Clinical Trial Agreement ( CTA)  
• Financial disclosure  
• Curriculum Vitae ( CV) of investigators and key members of the investigation study site team  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 31 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Documentation of delegated tasks  
• Documentation of study training  
• Additional requirements imposed by [CONTACT_427], the IRB and RA shall be followed, if 
appropriate.  
 
In addition,  all participating study site staff must be trained on the current version of the CIP as well as on 
the applicable study requirements depending on their role and must be delegated by [CONTACT_1961] [INVESTIGATOR_180984].   
Medtron ic will provide each study site with documentation of study site/investigator readiness; this letter 
must be received prior to performing study related activities.   
8.3 Role of the Sponsor Representatives  
Sponsor representatives may provide support at the stud y site as required for the study under supervision 
of the Principal Investigator, including:  
• Provide study training relevant and pertinent to the involvement of personnel conducting study activities and investigator responsibilities  
• Technical support under  the supervision of a study investigator, but no data entry, shall be 
performed by [CONTACT_230976]  
• Monitoring and auditing activities   
9. Selection of Subjects  
8.  
9.  
9.1. Study Population  
Up to 1 50 healthy, non -smoking (or has refrained from smoking for 2  days) volunteers, ages [ADDRESS_278173] been met. Subjects who give informed consent for the protocol in order to  undergo screening for eligibility are not 
considered enrolled and should not be enrolled u ntil the screening is completed  as indicated in Sections 
9.3, 9.4, and 10, and they are determined to meet all eligibility criteria. Study enrollment is accomplished  
by [CONTACT_230977]/exclusion criteria and 
health screening evaluation. Subjects who sign informed consent, but are not enrolled, are considered 
screen failures . 
 
9.3. Inclusion Criteria  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 32 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  1) Healthy (ASA physical status 1), male or female subjects between the ages of 18 to 60 years;  
2) Completion of a health screening for a medical histor y by a licensed physician, nurse practitioner 
or physician assistant ;  
3) Vital signs must be within the following ranges to be included: Vital signs measured sitting after [ADDRESS_278174]; heart rate: 45-90 bpm; systolic blood pressure: 110 -140; diastolic blood pressure: 
50-90. Out -of-range vital signs may be repeated once. [Pre- dose vital signs will be assessed by [CONTACT_1268] [INVESTIGATOR_1461] (e.g., a medically qualified sub -investigator) before study drug 
administration. The Principal Investigator [INVESTIGATOR_230905]-of-range vital signs and document approval before dosing] . 
 
9.4. Exclusion Criteria  
 
1) Has severe contact [CONTACT_230954] a reaction to standard adhesive materials found in 
pulse oximetry sensors, ECG electrodes, respi[INVESTIGATOR_230882], or other medical sensors 
[self -reported];   
2) Known neurological disorder (e.g., epi[INVESTIGATOR_002], the presence of a brain tumor, a history of brain 
surgery, hydrocephalic disorders, depression needing treatment with anti -depressive drugs, a 
history of brain trauma) [self- reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
3) Known cardiovascular disease (e.g., hypertension, coronary artery disease, prior acute myocardial 
infarction, any valvular and/or myocardial disease involving a decrease in ejection fraction, 
arrhythmias, which are either symptomatic or require continuous medication/ pacemaker/ 
automatic internal cardioverter defibrillator), current implanted pacemaker or automatic internal 
cardioverter defibrillator [self- reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
4) Has a clinically significant abnormal finding on medical history, physical examination, clinical 
laboratory tests, or ECG at the screening [self- reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
5) Use of psychoactive medication within the past 60 days (e.g., benzodiazepi[INVESTIGATOR_1651], antie pi[INVESTIGATOR_132385], Parkinson’s medication, anti -depressant drugs, opi[INVESTIGATOR_2438]) [self -reported and assessment by 
[CONTACT_976] [INVESTIGATOR_9232]];  
6) Subjects with known gastric diseases [self -reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
7) Has a positive urine cotinine test or urine dru g screen or oral ethanol test [POC testing];  
8) Known history of allergic or adverse response to drugs to be administered [self- reported];   
9) Known history of complications relating to previous general anesthesia or conscious sedation 
[self -reported and assessm ent by [CONTACT_976] [INVESTIGATOR_9232]];  
10) Known history of malignant hyperthermia [self- reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
11) Has a room air saturation less than 95% by [CONTACT_406] [measurement by [CONTACT_976] [INVESTIGATOR_9232]];  
12) Has a clinically significant abnormal pulmonary fun ction test via spi[INVESTIGATOR_038] [assessment by [CONTACT_976] [INVESTIGATOR_42550]];  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 33 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  13) Pregnant or lactating women [assessed by [CONTACT_230955]- reported];  
14) Subjects with tattooed skin specific to the sensor placement areas (forehead, fingers, chest) [self -
reported and assessment by  [CONTACT_976] [INVESTIGATOR_9232]];  
15) The subject must not take any prescription medication, except female hormonal contraceptives 
or hormone replacement therapy, from 14 days before the dosing until the end -of-study visit 
without evaluation and approval by [CONTACT_737]. Subjects who participated in a previous 
clinical trial who received a required FDA approved concomitant medication, for example, 
naltrexone, but were not randomized may be considered for participation in this study if they 
meet the washout requirement [ass essment by [CONTACT_976] [INVESTIGATOR_9232]].  
10.  Study Procedures  
10.  
10.1.  Schedule of Events  
The Schedule of Events, Table 3, summarizes the intervals and data collection procedures.  
Table 3: Schedule of Events  
Study Tasks  Pre-Screening  
Phone Visit  Enrollment  
Visit [ADDRESS_278175] 
(Female)   x x    
Complete blood count   x     
Inclusion/exclusion 
assessment   x x    
Vital signs   x x    
Concomitant Medication   x x    
Urine drug screen and 
alcohol breathalyzer    x    
Randomization to 
regimen group     x   
Safety Monitoring      x  
Sensors application      x  
Patient monitoring 
including raw data 
collection      x  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 34 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  Procedure with drug 
administration      x  
BIS™ , Pi[INVESTIGATOR_230884]4, 
MOAA/S , TES  assessments      x  
Safety Assessments and Compensation  
Adverse Event 
Assessment [ADDRESS_278176] be obtained prior to  any study -specific evaluations; for more 
details, refer to  Section 10.3 
2. All Adverse Events, regardless of relatedness or outcome, will be collected and reported  from the 
time of BIS ™ sensor application through 48 hours following procedure ; for more details, refer to  
Section 12 
3. Device Deficiency will be collected and reported; for more details, refer to  Section 12. 
4. Pi[INVESTIGATOR_230906], sevoflurane with 
remifentanil, and sevoflurane  with fentanyl groups.  
 
10.2.  Subject Pre- Screening/Screening  
Patients will be pre -screened for potential enrollment in the clinical study based on prior medical history 
and records.  
All subjects that are considered for the study should be included on the study screening log. The reason 
for non -eligibility, as determined by [CONTACT_230978]. 
The screening log serves as a method for Medtronic to assess selection bias in the trial.  
 
10.3.  Subject Consent  
At the enrollment visit, subjects will be approached to obtain written informed consent prior to any data  
collection. Once the signed and dated Informed Consent Form ( ICF) is collected, the screening of the 
subject will follow. The purpose of the study and the  benefits and risks of the procedures will be explained 
to the subject , and the consent process must be  documented. Subjects who agree to study participation 
must sign  the Institutional Review Board  (IRB) approved ICF. Consent to participate in this study mus t be 
given in writing. Subjects that are unable to give consent will not be included in the study.  A sample copy 
of the ICF will be maintained under separate cover.  
 The Investigator or authorized designee must obtain written informed consent before any cl inical study 
related activity takes place. Prior to entry into the study, the IRB and Medtronic -approved ICF form, and 
the Health Insurance Portability and Accountability Act (HIPAA) Authorization Form (if not included within 
the ICF) ( the US only) will be  given to each subject.  
The Investigator or authorized designee will fully inform the subject of all aspects of the clinical study that 
are relevant to the subject’s decision to participate in the clinical study (e.g. , purpose and duration of the 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278177] during the study, potential risks and possible benefits associated with 
participation in this study). All items addressed in the ICF must be explained. The language used shall be 
as non -technical as possible and must be understan dable to the subjects. The subject must have ample 
time and opportunity to read and understand the ICF , to inquire about the details of the clinical study, 
and to decide whether or not to participate in the clinical study. All questions about the clinical study 
should be answered to the satisfaction of the subject. In the case that a subject is unable to read, an 
impartial witness must also be present and sign the informed consent to confirm that the research has 
been clearly explained and all of the subjec t’s questions have been answered.  
 
Neither the Investigator nor the investigation site staff shall coerce or unduly influence a subject to 
participate or to continue to participate in the clinical study. The informed consent process shall not waive 
or app ear to waive the subject’s rights. When the subject decides to participate in the clinical study, the 
HIPAA Form (if applicable) and the ICF must be personally signed and dated by [CONTACT_423].  
 After the subject ha s signed and dated the ICF, the Investiga tor must provide the subject with a copy.  
 Medtronic will inform the Investigators whenever information becomes available that may be relevant to 
the subject’s confirmed participation in the clinical study. The Investigator or his/her authorized designee  
should inform the subject in a timely manner.  
 Medtronic will revise the written ICF  whenever new information becomes available  that may be relevant 
to the subject’s confirmed participation in the clinical study. The revised information  will be sent to the  
Investigator for approval by [CONTACT_1201]. After approval by [CONTACT_1201], a copy of this  information must be provided 
to the participating subjects, and the informed consent process , as described above , needs to be repeated.  
 
10.4.  Enrollment - Visit 1  
After successful completion of the pre -screening, qualified subjects will be invited to attend Visit 1 to 
complete the ICF. The Investigator or designee will inform the prospective subjects on the study 
procedures and explain the consenting process.  Once ICF is signed, the  following will be performed during 
the screening:  
• Demographics ( race, ethnicity,  sex, height, weight, skin tone, calculated body mass index 
(BMI) ) will be recorded on the eCRFs ; 
• Medical History  will be evaluated and documented to evaluate for prior or existing medical 
conditions and/or procedures that would exclude subjects from participation in the study ; 
• Physical examination including an evaluation of general appearance, cardiovascular, 
respi[INVESTIGATOR_230907], skin, neurologic function, an d head, eyes, ears, nose and 
throat;  The American Society of Anesthesiologist (ASA) physical status classification system is 
used to evaluate the degree of a patient's "sickness" or "physical state.” Only subjects with 
ASA Physical status 1 will be enrolle d; 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 36 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Concomitant Medications , including the history  of prescription and over the counter 
medication , will be carefully noted and recorded. Medication name, indication for use, dose, 
frequency, route of administration start/stop date  will be recorded on the eCRFs ; 
• Vital signs -  Heart Rate, Systolic , and Diastolic Blood Pressures, Respi[INVESTIGATOR_230908] (SpO 2) will be evaluated ;   
• Single 12 -lead ECG;   
• Complete blood count (CBC) ; 
• Urinary pregnancy test ; 
• A urine sample w ill be tested for the presence of cotinine (nicotine metabolite) to exclude 
smokers;  
• Subjects able to bear children  will have to attest to birth control methods;  
• Adverse event review will be completed to assess events at baseline , and that occur after 
enro llment.   
The Enrollment  results and informed consent will stay valid  for 60 days .  
 
10.5.  Execution – Visit 2  
Pre-Procedure   
• On the study day, subjects will arrive at the clinical research unit with appropriate fluid and solid 
intake as directed by [CONTACT_464]. The subject will be instructed not to consume beverages and 
foods containing alcohol, grapefruit, or caffeine/xanthine from [ADDRESS_278178].  
• Any significant change in health status since  Visit 1 will be recorded.  
• Concomitant Medication  and adverse events  will be checked . 
• All subjects will have urine drug screen and alcohol breathalyzer (Oral Ethanol) tests done.   
• Subjects  of child -bearing potential will also have a urine pregnancy test do ne. 
• Review Inclusion and Exclusion Criteria re-checked based on additional information.  
• Enrollment Pass is based upon successful inclusion /exclusion criteria during Visits 1 and 2  with 
investigator sign -off. 
Randomization  
At Visit 2, all subjects who satisfy all the entry criteria will be equally randomiz ed to each group of 
anesthetics regimens , stratifying by [CONTACT_3725].  Randomization schedules will be created by a n independent  
statistician , and randomization assignments will be  automatically populated on the Randomization e -CRF.  
Once subjects are assigned to a study group, they are  considered randomized.  All randomized subjects  
should be encouraged to comply with the study procedures until the end of the study.    
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278179]’s safety, an anesthesiologist authorized to administer sedation drugs will be responsible 
for administering any procedural drugs for the sedation and monitoring of subject safety and physical  
state. All other personnel involved with the safety monitoring of subjects must be trained in and familiar 
with the management of recovery of sedated patients. The study site should utilize  a setting that is fully 
equipped for the monitoring and support o f the subject’s respi[INVESTIGATOR_230899]. Subjects 
will be continuously monitored throughout the study.  
All subjects will be monitored during procedure using an electrocardiogram (ECG), Pulse Oximeter for 
SpO 2, and capnography (or another sy stem) for Respi[INVESTIGATOR_230909] 2. A clinician will be monitoring 
respi[INVESTIGATOR_230910]. The respi[INVESTIGATOR_230911], adequate oxygenation (SpO
2 >92%), and CO [ADDRESS_278180] (with or without manually assisted breathing), insertion of an airway device (oropharyngeal airway or laryngeal mask airway) and/or inte rmittent positive pressure 
ventilation (IPPV). Mask or nasal cannula will be used for supplemental O [ADDRESS_278181]’s safety.  For patient safety, modifications to 
the procedure steps will be left to th e judgment of the Principal Investigator (PI).  
 Regimen Set -Up  
The opi[INVESTIGATOR_2438] (remifentanil or fentanyl) will be administered via the target -controlled infusion (TCI)  pump 
using either the p reprogrammed pump protocols or computer -controlled program, e.g., TIVA Trainer, or 
another computer -controlled program, to ensure that the targeted effect- site concentration of a drug is 
reached and maintained at each drug concentration plateau. 1 % propofol and remifentanil or fentanyl 
diluted to a single concentration of 50 µg/ml will be used  in this study. The i nfusion rate between 0 and 
1200 ml/hr will be used to achieve a targeted concentration of remifentanil and fentanyl. For 
remifentanil, Minto [1, 46]  PK/PD model will be used. The kinetic model for fentanyl will not be weight -
adjusted  [2]. Phenylephrine may be provided  at a concentration of 100 mcg/mL  and lidocaine can be 
administered per Investigator discretion as a bolus over 3 -5 seconds at a maximum concentration of 
100mg.  Antiemetic / anti -nausea medication (i.e. Ondansetron ) may be used prophylactically on all 
subjects at the investigator’s discre tion.  
 Inhalation anesthetic drugs will be administered via a tight -fitting face mask or a laryngeal mask (LMA). 
Subjects will be connected to a circular breathing system of an anesthesia machine. After the subject loses 
responsiveness, a laryngeal mask airway (LMA) may be inserted as needed to facilitate airway control at 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 38 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  deeper levels of anesthesia. Inhalation agents will be administered with O 2 to maintain saturation of 
greater than 90%.  
Sensor Application  
The BIS™ sensor will be applied per its IFU. Su bjects will have an intravenous catheter inserted for fluid 
and drug administration.  The TES sensor will be applied per its IFU. A stimulation of 2-5mA, [ADDRESS_278182] 12 minutes before starting any regimen.  
 
MOAA/S , Pi[INVESTIGATOR_230912] (TES)  
 At each steady -state step and after equilibration, the MOAA/S assessment will be administered by [CONTACT_230979]. The same anesthesiologist , trained and delegated to perform the MOAA/S assessment 
on the Delegation of Tasks Log  must perform all MOAA/S assessment s for a specific subject,  refer to 
Appendix A . The maximum number of delegated Anesthesiologists per site to perform the MOAA/S 
assessment is two in order to ensure consistency across physicians.  
 
Subjects  in the sevoflurane, sevoflurane with remifentanil and sevoflurane with fentanyl regimens  will 
then be assessed using a Pi[INVESTIGATOR_230913] a standard set of [ADDRESS_278183] set of control pi[INVESTIGATOR_230914]/S assessment. The 
second set of control pi[INVESTIGATOR_230915] -state step following the MOAA/S 
assessment and the third  set of control pi[INVESTIGATOR_230916] -state step following the 
MOAA/S assessment. If the subject is still awake at the fourth step, they will be shown a fourth set of 
control pi[INVESTIGATOR_230917]/S assessment.  At each step, the subject will be asked to confirm 
that they can see the pi[INVESTIGATOR_230918], the pi[INVESTIGATOR_230919]. Once the subject is deemed ready for discharge, they will 
be shown the [ADDRESS_278184] was able to identify and whether they were control or distractor pi[INVESTIGATOR_499].  
 
Each site will be provided with 7 standardized sets  of pi[INVESTIGATOR_499]. Three (3) to [ADDRESS_278185].  
 
Subjects will receive noxious electrical stimulation us ing Tetanic Electrical Stimulation (TES) once they 
achieve a MOAA/S score  = 0, BIS™ value < [ADDRESS_278186]. The BIS™ value will be recorded, followed by [CONTACT_230967]/S 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 39 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  assess ment. Then, TES will be initiated following the Instructions for Use (IFU) for the XAVANT STIMPOD™ 
NMS 410/450X device.  TES will then be initiated once the subject reaches a MOAA/S 0, BIS™ value <[ADDRESS_278187] does not purposefully (i.e. attempting to push the stimulus away) respond, the 
stimulation will increase to 30mA, 50Hz for [ADDRESS_278188] will be considered a non -
purposeful responder (i.e. exhibiting a reflex withdrawal, facial grimace, or groan) and their response such 
as withdrawal of extremity, facial grimace or other will be recorded along with the BIS™ value prior to 
stimulation, at the  end of all assessment s and approximately [ADDRESS_278189] does respond to any of the stimulations with a purposeful response, the TES will be ended, the 
response will be noted and the BIS™ value will be recorded at the time TES is ended at approximately [ADDRESS_278190] is 
conscious.   
Sevoflura ne Group 
After approximately 2 minutes of baseline measurement,  sevoflurane will be administered in steps to 
achieve a loss of consciousness  via a tight -face mask  by [CONTACT_230957] -tidal concentration of 
Sevoflurane (ET SEVO). Targeted concentration for  ETSEVO are 0.2, 0.5, 0.7, 1,  2, 3, 4, 5% or higher until a 
BIS™ value not less than 30 is reached or per Investigator’s discretion. The BIS ™ value should  
be taken to at least 40, but not intentionally below 30. . The equilibration time for each targeted 
concentration will be approximately 12 minutes to maintain a constant ET SEVO.  
The BIS ™ value, MOAA/S score and pi[INVESTIGATOR_230920]. TES will then be initiated 
once the subject reaches a MOAA/S =0 and the BIS ™ value <[ADDRESS_278191] concentration of 
anesthesia anticipated . The BIS ™ value will be recorded at the time of subject’s response and 
approximately [ADDRESS_278192] -site targeted concentration of 
remifentanil of 4 ng/ml, an initial IV bolus of remifentanil will be given followed by [CONTACT_230959]. Approximately within [ADDRESS_278193]- site concentration of remifentanil of 4 ng/ml.  
Sevoflurane will be administered via a tight -face mask in steps to achieve a loss of consciousness by 
[CONTACT_230957] -tidal concentration of sevoflurane (ET SEVO). Targeted concentration for ET SEVO are 0.2, 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 40 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  0.5, 0.7, 1,  2, 3, 4, 5% or higher until a BIS ™ value not less than 30 is reached or per Investigator’s 
discretion. The BIS ™ value should be taken to at least 40, not intentionally below 30.    
The equilibration time for each targeted plateau will be approximately 12 minutes. The BIS ™ value, 
MOAA/S sco re and pi[INVESTIGATOR_230921]. TES will then be initiated once the subject reaches a MOAA/S =  0 and the BIS ™ 
value <  [ADDRESS_278194] concentration of anesthesia anticipated . The BIS ™ value will be recorded at the 
time of subject’s response and approximately 2 minutes following the TES assessment.  
ETSEVO is decreased by [CONTACT_230960].  
The cardiac output will be monitored, and subjects could be discontinued per PIs discretion . The 
respi[INVESTIGATOR_135890] 4 breaths/min or less will be considered evidence of remifentanil -induced respi[INVESTIGATOR_41826], and remifentanil will be discontinued.  
Sevoflurane with Fentanyl Group  
Approximately [ADDRESS_278195] -site targeted concentration of 
fentanyl of 2 ng/mL, an initial IV bolus of fentanyl will be given followed by [CONTACT_230958]. 
Approximately within [ADDRESS_278196]-
site concentration of fentanyl of 2 ng/ml.  
Sevoflurane will be administered via a tight -face mask in steps to achieve a loss of consciousness by 
[CONTACT_230957] -tidal concentration of sevoflurane (ET SEVO). Targeted concentration for ET SEVO are 0.2, 
0.5, 0.7, 1,  2, 3, 4, 5% or higher until a BIS ™ value not less than 30 is reached or per Investigator’s 
discretion. The BIS ™ value should be taken to at least 40,  but not intentionally below 30.   
The equilibration time for each targeted plateau will be at least 12 minutes.  
The BIS ™ value, MOAA/S scor e and pi[INVESTIGATOR_230922]. TES will then be initiated once the subject reaches a MOAA/S =  0 
and the BIS ™ value <  [ADDRESS_278197] concentration of anesthesia anticipated . The BIS ™ value will be 
recorded at the time of subject’s response and approximately 2 minutes following the TES assessment.   
ETSEVO is decreased by [CONTACT_230960].  
The cardiac output will be monitored, and subj ects could be discontinued per PIs discretion . The 
respi[INVESTIGATOR_135890] 4 breaths/minute or less will be considered evidence of fentanyl- induced respi[INVESTIGATOR_41826], and fentanyl will be discontinued.  
Desflurane Group  
Due to desflurane being a volatile agent and not well tolerated as an induction agent, an initial IV bolus 
of 1% propofol provided at 2mg/kg, with supplemental boluses given at the investigators discretion in 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 41 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  order to achieve LMA insertion, will be administered 0 -15 minutes prior to desflurane. Per Investigator’s 
discretion and allowed by [CONTACT_230980], once  correct LMA placement has been confirmed, there will be 
an equilibrium time of approximately [ADDRESS_278198] of consciousness as measured by a  MOAA/S 
score of 2 or 3. Desflurane will then be administered via a tight -face mask at the targeted end -tidal 
concentration (ET DES) of 2, 5, 7, 8, 9, 10 %, or higher until a BIS ™ value not le ss than 30 is reached or per 
Investigator’s discretion. The BIS ™ value should not intentionally be taken below 30.  
The equilibration time for each targeted plateau will be approximately 12 minutes. The BIS ™ value  and 
MOAA/S score  will be assessed when the patient is awake and at the different ET DES concentrations. TES 
will then be initiated once the subject reaches a M OAA/S = 0 and the BIS ™ value <  [ADDRESS_278199] 
concentration of anesthesia anticipated . The BIS ™ value will be recorded at the time of subject’s 
response and approximately 2 minutes following the TES assessment.   
The BIS ™ value will be correlated with d esflurane ET DES concentration. LMA should be removed at the 
highest level of sedation while maintaining subject’s safety in order to allow for a gradual emergence 
from anesthesia.  ETDES is decreased by [CONTACT_230960].  
Isoflurane Group  
Due to isoflurane being a volatile agent and not well tolerated as an induction agent, an initial IV bolus of 1% propofol provided at 2mg/kg, with supplemental boluses given at the investigators discretion in 
order to achieve LMA insertion , will be administered 15 -20 minutes prior to isoflurane. Per Investigator’s 
discretion and allowed by [CONTACT_230980], once  correct LMA placement has been confirmed, there will be 
an equilibrium time of approximately [ADDRESS_278200] of consciousness as measured by a  MOAA/S 
score of 2 or 3. Isoflurane  will be administered via a tight -face mask in steps to achieve a loss of 
consciousness (MOAA/S of 0,1)  by [CONTACT_230957] -tidal concentration of Isoflurane (ET
ISO). Targeted 
concentration for ET ISO are 0.25, 0.5, 0.75, 1, 1.5% or higher until a BIS ™ value not less than 30 is reached 
or per Investigator’s discretion. The BIS ™ value should be taken to at least 40,  but not intentionally 
below 30.    
The equilibration time for each targeted concentration will be approximately 12 minutes to maintain a 
constant ET ISO. The BIS ™ value  and MOAA/S score will be assessed when the patient is awake and at the 
differe nt ET ISO concentrations. TES will then be initiated once the subject reaches a MOAA/S =  0 and the 
BIS™ value <  [ADDRESS_278201] concentration of anesthesia anticipated . The BIS ™ value will be recorded 
at the time of subject’s response and approximately 2 minutes following the TES assessment.   
The BIS ™ value will be correlated with desflurane ET ISO concentration. LMA should be removed at the 
highest level of sedation while maint aining subject’s safety in order to allow for a gradual emergence 
from anesthesia.  ETISO is decreased by [CONTACT_230960].  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278202] -site concentrations, infusion r ate, the start and end time s 
of the assessment s including BIS™  value prior to  and after  MOAA/S and TES assessment s will be recorded 
in the electronic Case Report Forms (eCRFs). Any adjustments to the infusion rate and time of adjustment 
will be recorded, and any changes to subject management during the procedure will be noted on the 
eCRFs.  
Raw Device Data Collection  
The device data (raw signals), including Heart Rate, Blood Pressure, Respi[INVESTIGATOR_26452], EtCO 2, SpO 2, BIS™, 
TCI if available, will be collected  in real- time during the procedure . The BIS™  data will be recorded with a 
USB memory stick connected to the monitor . Periodically, the raw device data will be transferred directly 
to the Medtronic secure server for data quality review and analysis . The instructions on the secure data 
transfer will be provided by [CONTACT_13735].  
 
10.6.  Follow -up  
Phone Call  
The site will attempt to contact [CONTACT_230981] [ADDRESS_278203] the  following questions:  
• Have you had any medical problems since your discharge from the clinical research unit?  
• Have you taken any medications (either prescribed or self- medicated) since discharge from the 
clinical research unit?  
 
10.7.  Assessment of Efficacy  
Refer to Section 14. 
 
10.8.  Assessment of Safety  
For safety analyses, adverse events will be summarized using frequency counts and percentages , refer to 
Section 14. Descriptive statistics will be provided by [CONTACT_92920], severity , and relationship to study 
procedures and  devices. Individual listings of adv erse events, including event type, start date, duration, 
severity, and  device -relatedness , will be provided as appropriate . For device -related events refer to 
Section 12 . Adverse events occurring from the time of BIS ™ sensor application to  48 hours after the 
procedure will be recorded . For AEs and AE reporting requirements , refer to Section 12. 
 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 43 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  10.9.  Recording Data  
The study will utilize the electronic Case Report Forms (eCRFs)  in a database provided by [CONTACT_1034] . All 
eCRFs will be completed using the assigned subject identification number.    
eCRF completion may be delegated by [CONTACT_079] (documented on the Delegated Task List) 
to other study personnel , but the Principal Investigator [INVESTIGATOR_230923]. The Principal Investigator [INVESTIGATOR_230924] -Investigator is required to 
approve all data on eCRFs via electronic signature.  
 
Additional details regarding procedures used for data review, dat abase cleaning, issuing and resolving 
data queries, and identification of steps for creation, modification, maintenance, archiving retrieval or transmission of source data via any computerized systems will be provided in the study -specific Data 
Management Plan (DMP).  
 
10.10.  Deviation Handling  
The investigator is required to conduct this study in accordance with the protocol, Good Clinical Practice 
(GCP), Institutional Review Board ( IRB) requirements, and applicable regulations. The investigator is not 
allowed to deviate from the above -mentioned documents except under emergency circumstances to 
protect the rights, safety, and well -being of human subjects.  
 
A study deviation is defined as an event when the investigator or site personnel did not conduct the study according to the protocol or the clinical trial agreement.  
The investigator is required to obtain prior approval from the sponsor and IRB before  initiating deviations 
from the Clinical Investigation Plan , except where necessary to protect the life or safety a nd physical well-
being of a subject in an emergency. Such approval will be documented in writing and maintained in the 
study investigator files.  
 Major deviations are defined as deviations with respect to:  
• Patient informed consent procedure;  
• Patient eligibility criteria;  
• Serious Adverse Event/Serious Adverse Device Effect/Unanticipated Adverse Device Effect 
/Unanticipated Serious Adverse Device Effect reporting ( for reporting refer to  Section 12). 
 
Deviations will be recorded at the site and reported to Medtronic on the eCRF. The deviation document 
shall be signed and dated by [CONTACT_230982]. At a minimum, the following 
information will be recorded:  
• identification of the investigator and site  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 44 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • description of deviation  
• date of occurrence  
• reason for the deviation  
• patient identifier, if associated with the event  
 
Deviations will be entered into a database to allow a comprehensive review on a regular basis for 
identifying  trends that warrant additional preventive or corrective actions to mitigate further occurrence. 
Clinical study management at Medtronic shall conduct this review. Repetitive or serious in vestigator 
compliance issues may result in the need to initiate a corrective action plan, and in some cases, freeze 
enrollment or ultimately terminate the investigator’s participation in the clinical study.  
 
Study deviations must be reported to Medtronic, regardless of whether medically justifiable, pre -
approved by [CONTACT_230983] (see contact [CONTACT_230984] ) or taken to protect the subject in an emergency.  
 In the case that the deviation involves a failure to obtain a subject’s informed consent or is made to 
protect the life or physical well- being of a subject in an emergency, the deviation must be reported to the 
IRB as well as the study leader as soon as possible after the occurrence of the event. Reporting of all other 
study deviations should comply w ith IRB policies and/or local laws.  
 
10.11.  Subject Exit, Withdrawal or Discontinuation  
There are many scenarios in which a subject may exit the study. The f ollowing terms are used for 
withdrawal and completion:  
• Screen Failure: Did not meet the study inclusion/exclusion criteria;  
• Study Withdrawal: Removal from the study after Enrollment by [CONTACT_230985], PI, or Sponsor, or 
technical problems;  
• Study Complete: Completion of all study related activity by [CONTACT_423];  
• Lost to Follow up: Subjects lost to follow -up will be documented.  
The investigator should make every attempt to contact [CONTACT_230986] -up phone call within 48 hours or to determine the occurrence/resolution of adve rse events (if any) 
refer to Section 9.6. 
It is the subject’s right to withdraw from the study at any time and for any reason without sanction, 
penal ty or loss of benefits to which the subject is otherwise entitled, and without jeopardizing their future 
medical care. The investigator may withdraw the subject at any time to protect the health, safety , or 
welfare of the subject. Every effort should be made to collect the status of any ongoing adverse events, 
at a minimum.  All subjects will be encouraged to remain in the study through the follow -up phone call.  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278204]’s study records and e CRF.  
 
If withdrawal from the study is due to problems related to the investigational device safety or 
performance, the i nvestigator shall ask for the subject’s permission to follow his/her status outside the 
clinical study.  
11. Risks and Benefits 
11.  
11.1.  Potential Risks  
Risks to participation are primarily physical. There are no social, economic, legal, long -term psychological, 
or other risks that have been identified. Risks under this protocol relate to both study devices and study 
procedures. We believe that the risks f rom the device(s) are in keepi[INVESTIGATOR_42556] -
significant risk devices (NSR). Further, the devices in this study are non -invasive, and the clinical protocol 
design is minimal risk to the subject. No treatment or treatment decisions will be made during the course of this study. Following is a list detailing potential risks from study devices and the clinical protocol.  
  
11.2.  BIS™ Sensor Risks  
The BIS™ Sensor is applied directly to the patient’s skin to enable recordings of electrophysiological (suc h 
as EEG) signals. The sensor will be used as per IFU. The sensors used in this study may expose subject s to 
the following risks:  
• Minor discomfort , allergic reaction, or skin irritation ( such as redness, itching) at the sensor 
application site is probable  but is usually self- limited within hours.  
• Pressure points/ injury in application areas are possible but anticipated to be rare due to the short 
duration of the study. Care in the application and removal of the sensors is advised. Skin reactions 
will be o bserved during and after the study procedures.  
• Electric shock is very rare, and the product design and testing ensure insulation and ground fault 
detection.  
• Burn to the skin (due to a small amount of heat generated) is a rare unanticipated risk, and not likely due to the short duration of the study.  
 
Some Sensor Warnings and Cautions are listed below, for more information on warnings and cautions, 
refer to Sensor IFU.  
 
Warnings:  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 46 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • To reduce the hazard of burns during use of brain -stimulating devices (e.g., transcranial electrical 
motor evoked potential), place stimulating electrodes as far as possible from the bis sensor and 
place sensor according to instructions.  
 
Cautions: 
• Patient position may increase the risk of skin irri tation on the forehead. With patients in prone 
position, consider minimizing pressure on the sensor.  
• Do not use if sensor is dry.  
• To avoid dry out, do not open pack until ready for use.  
• Due to intimate skin contact, reuse may pose risk of infection.  
• If skin rash or other unusual symptoms develop, stop use and remove.  
• Limited to short -term use (maximum 24 hours).  
• Do not cut sensor, as this will result in improper operation.  
• Upon removal, slight redness of skin may occur and typi[INVESTIGATOR_36065] a s hort period of 
time.  
 
11.3.  BIS™ Monitoring System Risks  
Monitoring System will be used per IFU. Some warnings are listed below, for more information on 
warnings and cautions refer to IFU.  
 
Warnings:  
• Explosion hazard: do not use the BIS™ complete system in a fl ammable atmosphere or where 
concentrations of flammable anesthetics may occur.  
• Monitor is not designed for use in MRI environment.  
• Use only the power cord supplied by [CONTACT_3455]. Never adapt the plug from the monitor 
to fit a non -standard outlet.  
• U.S.A. requirement: for proper grounding, the power receptacle must be a three -wire grounded 
outlet. A hospi[INVESTIGATOR_230925]. Never adapt the three -prong plug from the monitor to 
fit a two -slot outlet. If the outlet has only two slots, make sur e that it is replaced with a three -slot 
grounded outlet before attempting to operate the monitor.  
• If the integrity of the external protective earth ground is in doubt, the BIS™ complete system shall be operated from its internal battery power source only.   
• Be sure the monitor is mounted securely in place to avoid personal or patient injury.  
• The BIS™ complete monitor should not be used adjacent to or stacked with other equipment. If adjacent or stacked use is necessary, the BIS™ complete monitor should be observed to verify normal operation in the configuration in which it will be used.  
• When connecting external equipment (e.g., data capture computer), the system leakage current 
must be checked and must be less than the IEC [ZIP_CODE] -1-1 limit.  
• Using accessories other than those specified may result in increased electromagnetic emissions or decrea sed electromagnetic immunity of the BIS™ complete monitoring System.  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 47 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • The use of accessory equipment not complying with the equivalent safety requirements of this 
equipment may lead to a reduced level of safety of the resulting system. Consideration relating 
to the choice shall include: Use of the accessory in the patient vicinity. Evidence that the safety certification of the accessory has been performed in accordance to the appropriate IEC [ZIP_CODE] -1 
and/or IEC [ADDRESS_278205].  
• Due to  elevated surface temperature, do not place the BISx™ unit in prolonged direct contact [CONTACT_230987]’s skin, as it may cause discomfort.  
• The conductive parts of electrodes or sensor and connectors should not contact [CONTACT_230988], including earth.   
• To reduce the hazard of burns during use of high -frequency surgical equipment, the sensor or 
electrodes should not be located between the surgical site and the electro -surgical unit return 
electrode.  
• To reduce the hazard of burns during use of brain -stimulating devices (e.g., transcranial electrical 
motor evoked potential), place stimulating electrodes as far as possible from the BIS™ sensor and 
make certain that sensor is placed according to package instructions. The sensor must not be located between d efibrillator pads when a defibrillator is used on a patient connected to the BIS™ 
complete system.  
• To minimize the risk of patient strangulation, the patient interface cable (PIC) must be carefully placed and secured.  
• Shock Hazard: Do not attempt to disc onnect the power cord with wet hands. Make certain that 
your hands are clean and dry before touching the power cord.  
• Universal precautions shall be observed to prevent contact [CONTACT_230989]. Place contaminated materials in regulated waste container.  
• Do not mix disinfecting solutions (e.g., bleach and ammonia), as hazardous gases may result.  
• Electrical Shock Hazard: Do not remove monitor covers during operation or while power is connected to monitor.  
• Electrical Shoc k Hazard: The manufacturer's inspection of this apparatus verified that the ground 
leakage current and the patient safety current were less than the specified limits established by [CONTACT_230990]. As a matter of safe practice, the institut ion should conduct 
periodic tests to verify these currents.  
• Whenever an event such as spi[INVESTIGATOR_230926], re -test ground leakage current 
before further use.  
• Leakage current must be checked by a qualified biomedical engineering technician whenever instrument case is opened.  
• Power supply is internally fused. Replace power supply only with Covidien BIS™ Complete power supply.  
• Portable RF communications equipment (including peripherals such as antenna cables and external antennas) should be used no closer than 30 cm (12 inches) to any part of the BIS™ 
complete monitoring system, including cables specified by [CONTACT_3455]. Otherwise, degradation of the performance of this equipment could result.  
• Check Target Range alarm limits to ensur e they are appropriate for the patient being monitored 
with each use. Ensure Target Range alarm limits do not exceed the standard thresholds set by [CONTACT_230991].  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 48 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Do not decrease the adjustable alarm volume below ambient sound levels. Decreasing the alarm 
volume below ambient levels may compromise patient safety.  
• Explosion hazard: do not use the BIS™ complete system in a flammable atmosphere or where 
concentrations of flammable anesthetics may occur.  
• Use only the power cord supplied by [CONTACT_3455] . Never adapt the plug from the monitor 
to fit a non -standard outlet.  
• If the integrity of the external protective earth ground is in doubt, the BIS™ complete monitor 
shall be operated from its internal battery power source only.  
• Due to elevated surface t emperature, do not place BISx™ unit in prolonged direct contact [CONTACT_230987]’s skin, as it may cause discomfort.  
• The conductive parts of electrodes or sensor and connectors should not contact [CONTACT_230988], including earth.  
• To reduce the hazard of burns during use of high -frequency surgical equipment, the sensor or 
electrodes should not be located between the surgical site and the electro -surgical unit return 
electrode.  
• The sensor must not be located between defibrillator pads when a defibrillat or is used on a 
patient connected to the BIS™ complete system.  
• Check Target Range alarm limits to ensure they are appropriate for the patient being monitored 
with each use. Ensure Target Range alarm limits do not exceed the standard thresholds set by [CONTACT_230991].  
• Universal precautions shall be observed to prevent  contact [CONTACT_230992]. Contaminated materials should be disposed of in accordance with national and local waste disposal legislation and requirements.  
• Do not mix disinfecting solutions (e.g., bleach and ammonia) as hazardous gases may result.  
• Leakage current must be checked by a qualified biomedical engineering technician whenever an instrument case is opened.  
• A power supply is internally fused. Replace power supply only with Covidien BIS™ complete power supply.  
• Electrical Shock Hazard: The manufacturer’s inspection of this apparatus verified that the ground 
leakage current and the patient safety current were less than the specified limits established by [CONTACT_230990]. As a matter of safe practice , the institution should conduct 
periodic tests to verify these currents. Whenever an event such as spi[INVESTIGATOR_230926], re -test before further use.  
• Using accessories other than those specified may result in increased electromagnetic emi ssions 
or decreased electromagnetic immunity of the BIS™ complete monitoring system.  
• The BIS™ complete system should not be used adjacent to or stacked with other equipment. If adjacent or stacked use is necessary, the BIS™ complete monitor should be observed to verify normal operation in the configuration in which it will be used.  
 
11.4.  XAVANT STIMPOD™ Quantitative NMT Monitor  
STIMPOD™ Quantitative NMT monitor will be used per IFU. Some warnings are listed below, for more 
information on warnings and cautions refer to the IFU.  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 49 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  Warnings:  
• Use of cables or accessories other than those supplied with the STIMPOD may result in serious 
injury.  
• Maintenance on this device may only be performed by [CONTACT_230993].  
• Do not use the STIMPOD in close proximity to equipment that produces strong electromagnetic 
fields, such as high frequency surgical equipment. The cable leads could act as an antennae and 
dangerous currents could be induced as a result.  
• Do not apply the STIMPOD to patients with implanted electrical devices, such as cardiac pacemakers, without first consulting with an appropriate medical specialist.  
• The device should not be used adjacent to or stacked with other equipment and that if adjacent 
or stacke d use is necessary, the device should be observed to verify normal operation in the 
configuration in which it will be used.  
• The patient should avoid contact [CONTACT_230994], produce an electrical 
conductive connection with other equ ipment and/or enable capacitive coupling.  
• The cables should be positioned in such a way that they do not contact [CONTACT_230995].  
• Simultaneous connection of a patient to high frequency surgical ME equipment and the STIMPOD 
may result in burns and possible damage to the stimulator.  
• Operation in close proximity (e.g. 1m) to a shortwave or microwave therapy ME equipment may produce instability in the stimulator output.  
• Application of electrodes near the thorax may increase the risk of cardiac fibrillation.  
• No modification of the equipment is allowed.  
• Do not modify this equipment without authorization of the manufacturer.  
• If this equipment is modified, appropriate inspection and testing must be conducted to ensure 
continued safe use of the equipment.  
 
11.5.  Nellcor™ Pulse Oximeter  
Nellcor™ Pulse Oximetry  will be used per IFU. Some warnings are listed below, for more information on 
warnings and cautions refer to IFU.  
• Pulse and Tissue Oximetry Sensor placement involves positioning pulse and tissue o ximetry 
sensors on the subject in the same manner that is used on hospi[INVESTIGATOR_26328].  
• The sensors may be warm to the touch. Under normal operating conditions, (no fault conditions), 
the sensors are not expected to overheat. If the sensors are too warm, they will be removed 
immediately.  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 50 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • The sensors exert a minimal amount of pressure. Sensors may leave minor impressions at the 
sensor application site, which should fade and resolve within the day. They should not cause 
discomfort. If the sensors are too unc omfortable, they will be removed.  
• Adhesive sensors may cause some irritations to the skin in some subjects. Typi[INVESTIGATOR_230927], an allergic reaction can occur.  
• Removal of the sensor ma y cause pulling of the skin or hair, and this can be felt as pain.  
• The risk in the use of oximetry sensors is believed to be minor.  
• A heating pad or hot water bottles may be used on the hands to improve circulation. The subject may experience some mild dis comfort if the water is too warm. To minimize the discomfort, the 
subject will be asked if the heating is too warm, it will be turned on the lowest level possible for comfort, removed or additional separation will be used between the heater and the site fo r 
comfort.  
 
11.6.  General Anesthesia Risks  
There are some risks associated with general anesthetics, but the  anesthetics under study  are relatively 
safe when administered correctly . Although not all of these side effects may occur, if they do occur, they 
may ne ed medical attention. All subjects will be monitored by [CONTACT_230996] s closely for the 
effects.  The most common side effects of general anesthesia include sore throat due to the breathing 
tube, nausea, vomiting, dizziness,  bruising, or soreness from the IV drip, shivering and feeling cold, and 
difficulty passing urine. These may occur despi[INVESTIGATOR_230928].  For additional information 
related to potential medication , risks refer to Table [ADDRESS_278206]’s teeth. This risk increases if the subject has loose teeth or other dental problems. With any 
medication given, the subject could have an allergic reaction. Although rare, unexpected severe 
complications with anesthesia can occur and include, but not limited to, the remote possibility of 
infection, bleeding, drug reactions, blood clots, loss of sensation, loss of limb function, paralysis, stroke, 
brain damage, heart attack or death.  The anesthesiologist  will be present to minimize all risks related to 
anesthesia . 
 
Table 4: Possible Side Effe cts using Medication  
Possible side effects of remifentanil  but not limited to : 
 
• Blurred vision  
• Chest pain or discomfort  
• Confusion  
• Difficult or troubled breathing  
• Dizziness , faintness, or lightheadedness 
when getting up suddenly from a lying or 
sitting position  Less common side effects of remifentanil  but not limited to : 
 
• Bluish lips or skin  
• Chills  
• Decreased  cardiac output  
• Fast, pounding, or heartbeat or pulse  
• Feeling of warmth  
• Fever  
• Headache  
• Nausea or vomiting  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 51 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Irregular , fast or slow, or shallow 
breathing  
• Lightheadedness , dizziness, or fainting  
• Muscle stiffness or tightness  
• Pale or blue lips, fingernails, or skin  
• Short ness of breath  
• Slow or irregular heartbeat  
• Sweating  
• Unusual tiredness or weakness  
• Itchiness  
 
 • Nervousness  
• Not breathing  
• Pain after surgery  
• Pain in the shoulders, arms, jaw, or neck  
• Pounding in the ears  
• Problems with bleeding or clotting  
• Redness of the face, neck, arms, and 
occasionally, upper chest  
• Shivering  
• Allergic reactions  
 
Possible side effects of fentanyl but not limited to : 
• Black, tarry stools  
• Blurred vision  
• Chest pain  
• Confusion  
• Convulsions  
• Cough  
• Decreased urine  
• Difficult or labored breathing  
• Dizziness  
• Dry mouth  
• Fainting  
• Fever or chills  
• Increased thirst  
• Irregular heartbeat  
• Lightheadedness  
• Loss of appetite  
• Lower back or side pain  
• Mood changes  
• Headache  
• Muscle pain or cramps  
• Nausea or vomiting  
• Nervousness  
• Numbness or tingling in the hands, feet, or lips  
• Painful or difficult urination  
• Pale skin 
• Pounding in the ears  
• Rapid breathi ng 
• Sneezing  
• Sore throat  
• Sunken eyes  
• Swelling of the hands, ankles, feet, or lower legs 
• Tightness in the chest  
• Troubled breathing with exertion  
• Ulcers , sores, or white spots in the mouth  Less common side effects of fentanyl but not limited to : 
• Abdominal or stomach pain  
• Change in walking and balance  
• Clumsiness or unsteadiness  
• Decreased awareness or responsiveness  
• Decreased frequency of urination  
• Headache  
• Muscle twitching or jerking  
• Pounding in the ears  
• Rhythmic movement of the muscles  
• Seeing, hearing, or feeling things that are not there  
• Seizures  
• Severe constipation  
• Severe sleepi[INVESTIGATOR_008]  
• Shakiness in the legs, arms, hands, or feet  
• Slow or fast heartbeat  
• Thinking abnormalities  
• Trembling or shaking of the hands or feet  
 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 52 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Unusual tiredness or weakness  
• Wrinkled skin 
Possible side effects of sevoflurane but not limited to : 
• cough  
• Dizziness  
• Drowsiness  
• Increased amount of saliva  
• Nausea /vomiting  
• Shivering  
• Laryngospasm  
• Airway obstruction  
• Breath holding  
• Apnea  
• Respi[INVESTIGATOR_44447]  
• Headache  
• Hypotension  
• Hypertension  
• Agitation  
• Bradycardia  
• Hypotension  
• Bradycardia  
• Tachycardia  
• Malignant hyperthermia  Less common side effects of sevoflurane but not limited to : 
• Dry mouth  
• Arrhythmia , ventricular extrasystoles, 
supraventricular extrasystoles, complete AV block, 
bigeminy, inverted T wave, atrial fibrillation , atrial 
arrhythmia, second degree AV block, S -T depressed, 
extrasystoles  
• Sputum increased, hypoxia, wheezing, 
bronchospasm, hyperventilation, 
pharyngitis , hiccup, hypoventilation, 
dyspnea , stridor, hypoxia, asthma  
• Pulmonary edema  
• Increases in LDH, alkaline phosphatase, 
hypophosphatemia, acidosis, hyperglycemia  
• Blood glucose abnormal  
• Urination  impaired, urine abnormality, urinary 
retention , oliguria  
• Rash  
• Muscle twitching  
• Syncope, hypertonia, taste perversion  
• Seizures, dystonia  
• Asthenia , pain, fluorosis  
• Allergic reactions  
Possible side effects of desflurane but not limited to :   
• Bluish lips or skin  
• Body aches or pain  
• Congestion  
• Cough  
• Dryness or soreness of the throat  
• Fever  
• Hoarseness  
• Not breathing  
• Runny nose  
• Tender , swollen glands in the neck  
• Tightness in the chest  
• Trouble breathing  
• Trouble swallowing  
• Voice changes  Less common side effects of desflurane but not limited to :  
• Blurred vision  
• Chest pain or discomfort  
• Dizziness  
• Fast, pounding, or irregular heartbeat or pulse  
• Headache  
• Lightheadedness , dizziness, or fainting  
• Nervousness  
• Pounding in the ears  
• Slow or irregular heartbeat  
• Unusual tiredness  
• Allergic reactions  
 
Possible side effects of isoflurane but not limited to:   
• Nausea  
• Vomiting  
• Shivering  
 Less common side effects of isoflurane but not limited to:  
• Dose -dependent hypotension  
• Arrhythmias  
• Malignant hyperthermia  
• Elevations in white blood cells  
• Decrease in creatinine and increase BUN  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 53 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Ileus, severe  
• Hepatic dysfunction  
• Respi[INVESTIGATOR_230929]  
• Hypotension  
• Apnea lasting 30 -60 sec  
• Apnea lasting >60 sec  
• Movement  
• Injection site burning/stinging/pain  
• Respi[INVESTIGATOR_230930]  
• Hypertriglyceridemia  
• Hypertension  
• Rash  
• Pruritus  
• Arrhythmia  
• Bradycardia  
• Cardiac output decreased concurrent opi[INVESTIGATOR_230931])  
• Tachycardia  Less common side effects of propofol but not limited to  
• Arterial hypotensi on 
• Anaphylaxis  
• Asystole  
• Bronchospasm  
• Cardiac arrest  
• Seizures  
• Opi[INVESTIGATOR_230932] 
• Pancreatitis  
• Pulmonary edema  
• Phlebitis  
• Thrombosis  
• Renal tubular toxicity  
• Allergic reactions  
Possible side effects of lidocaine but not limited to  
• Hypotension  
• Edema   
• Injection site burning/stinging/pain  
• Small purple or red spots on skin  
• Skin irritation  
• Constipation  
• Nausea  
• Vomiting   
• Confusion  
• Dizziness  
• Headache  
• Numbness and tingling  
• Drowsiness 
• Tremor  
•   Less common side effects of lidocaine  but not limited to  
• Cardiac Arrest  
• Abnormal Heartbeat  
• Methemoglobinemia  
• Seizures  
• Severe allergic reaction  
• Malignant hyperthermia  
Possible side effects of phenyl epherine  but not limited to  
• Blurred vision  
• Chest pain or discomfort  
• Difficult or labored breathing  
• Dizziness  
• Fainting  
• Fast, slow or irregular heartbeat  
• Headache  
• Nausea or vomiting  
• Nervousness  
• Pain in shoulders, arms, jaws or neck  
• Pounding in the ears  Less common side effects of phenylepherine  but not limited to  
• Feeling of fullness in the head  
• Pounding or rapid pulse  
• Tingling in the arms or legs  
• Vomiting   
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 54 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Sweating  
• Tightness in the chest  
• Unusual tiredness   
Possible side effects of ondansetron but not limited to  
• headache 
• constipation  
• weakness  
• tiredness  
• chills  
• drowsiness  Less common side effects of ondansetron but not limited to  
• blurred vision or vision loss  
• rash 
• hives  
• itching  
• swelling of the eyes, face, lips, tongue, throat, hands, 
feet, ankles, or lower legs  
• hoarseness  
• difficulty breathing or swallowing 
• chest pain  
• shortness of breath  
• dizziness, light- headedness, or fainting  
• fast, slow or irregular heartbeat  
• agitation  
• hallucinations (seeing things or hearing voices that do 
not exist)  
• fever  
• excessive sweating  
• confusion  
• nausea, vomiting, or diarrhea  
• loss of coordination  
• stiff or twitching muscles  
• seizures  
• coma (loss of consciousness)  
 
11.7.  Potential Benefits  
There are no medical benefits to the subjects who participate in this study. There is, however, the 
potential for benefiting future subjects should this study enable the development of improved medical 
monitoring devices.  
 
11.8.  Risk-Benefit Rationale  
Medtronic has determined that this is a study o f a “non -significant risk device” due to the nature of the 
devices being tested . Utilizing the FDA criteria1,2 listed below to distinguish between significant and non -
significant risk devices, Medtronic has determined that:  
• The investigational devic e is not intended as an implant and does not present a potential for 
serious risk to the health, safety, or welfare of a subject;  
• The investigational device is not purported or represented to be for use supporting or 
sustaining human life and does not pre sent a potential for serious risk to the health, safety, 
or welfare of a subject;  
 
1 21CFR812.2  (b)(1)(ii) and 21CFR812.3(m)  
2 Information Sheet Guidance For IRB/EC , Clinical Investigators, and Sponsor. Significant Risk and Non -significant Risk Medical Device Studies/  
January 2006/UMC126418  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 55 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • The investigational device is not for a use of  substantial importance in diagnosing, curing, 
mitigating, or treating disease, or otherwise preventing impairment of human health, and 
does not present a potential for serious risk to the health, safety, or welfare of a subject; and  
• The investigational device does not otherwise present a potential for serious risk to the health, safety, or welfare of a subject.  
 
The potential ri sks of these devices have been assessed and are not greater  than those of currently 
approved and marketed devices of the same type ( e.g., pulse and tissue oximeters, EtCO
2 monitors, non -
invasive blood pressure monitors, ECG or respi[INVESTIGATOR_230933]). Society may benefit from more accurate 
medical monitors.  
 
Medtronic  requests that the reviewing IRB  indicates  its agreement with this determination of non -
significant risk devic e in its letter of approval for this study.  
12. Adverse Events and Device Deficiencies  
 
12.1.  Adverse Events  
AE definitions are provided in Table 5 . AEs will be collected throughout the study from the BIS™ sensor 
application through [ADDRESS_278207] possibly related to the study will be followed 
until resolved, stabilized, and/or returned to baseline.  
Reporting of these events to Medtronic will occur on an AE Form. Each event must be reported separately. Documented pre- existing conditions are not considered AEs unless the nature or severity of the condition 
has worsened.  
 
For AEs that require immediate reporting (see Table 6), initi al reporting may be done by [CONTACT_648], fax, or on 
the CRF completing as much information as possible. The completed AE CRF must be submitted to 
Medtronic as soon as possible.   
 
Any medication/treatment associated with the treatment of an AE must be reported .  
Subject deaths are also required to be reported.  
 
12.2.  Device Deficiency  
The DD definition is provided in Table [ADDRESS_278208] should be capt ured as an AE only.  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278209] led to a SADE (i.e., if suitable action had not been taken, if 
intervention had not been made, or if the circumstances had been less fortunate) require immediate 
reporting (see Table 5). 
 
12.3.  Processing Updates and Resolution  
For any changes in status of a previously reported adverse event or DD (i.e. change in actions taken, 
change in outcome, change in relatedness), information needs to be updated on, or added to the original 
AE or DD form. A ll AEs must be followed until the AE has been resolved, is unresolved with no further 
actions planned, the subject exits the study, or until study closure, whichever occurs first.  
In the event that a subject is exited from the  study prior to study comple tion, all efforts should be made 
to continue following the subject until all unresolved system or procedure related AEs, as classified by [CONTACT_093], are resolved, unresolved with no further actions planned, or [ADDRESS_278210] be reported.  
 
12.4.  Definitions/Classifications  
Table 5: Adverse Event and Device Deficiency Definitions  
General  
Adverse Event (AE)  Untoward medical occurrence, unintended disease or injury, or untoward clinical signs 
(including abnormal laboratory findings) in subjects, users or other persons, whether or 
not related to the investigational medical device and whether anticipated or  
unanticipated  
 
NOTE 1: This definition includes events related to the investigational medical device or 
the comparator.  
NOTE 2: This definition includes events related to the procedures involved.  
NOTE 3: For users or other persons, this definition is rest ricted to events related to 
investigational medical devices.  
(ISO [ZIP_CODE]:2020, 3.2)  
Adverse Device Effect (ADE)  AE related to the use of an investigational medical device  
 
NOTE 1: This definition includes AEs resulting from insufficient or inadequate 
instructions for use, deployment, implantation, installation, or operation, or any 
malfunction of the investigational medical device.  
NOTE 2: This definition includes any event resulting from an error use or from 
intentional misuse of the invest igational medical device.  
NOTE 3: this includes ‘comparator’ if the comparator is a medical device. (ISO [ZIP_CODE]:2020, 3.1)  
Device Deficiency (DD)  Inadequacy of a medical device with respect to its identity, quality, durability, reliability, 
usability, saf ety or performance.  
 
NOTE 1: DD include malfunctions, use errors and inadequacy in the information 
supplied by [CONTACT_143143].  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 57 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  NOTE2: This definition includes device deficiencies related to the investigational 
medical device or the comparator. (ISO [ZIP_CODE]:2020, 3.19)  
Relatedness  
Procedure Related  An AE that occurs due to any procedure.  
Seriousness  
Serious Adverse Event (SAE)  
 AE that led to any of the following  
a) death,  
b) serious deterioration in the health of the subject, users or other persons as 
defined by [CONTACT_10980]:  
1) a life -threatening illness or injury, or  
2) a permanent impairment of a body structure or a body function, including 
chronic disease, or  
3) in -patient or prolonged hospi[INVESTIGATOR_059], or  
4) medical or surgical intervention to prevent life -threatening illness or injury 
or permanent impairment to a body structure or a body function,  
c) fetal distress, fetal death or a congeni tal abnormality or birth defect including 
physical or mental impairment  
 
NOTE 1: Planned hospi[INVESTIGATOR_272] a pre- existing condition, or a procedure required by 
[CONTACT_10396], without serious deterioration in health, is not considered an SAE.  
(ISO [ZIP_CODE]:2020, 3.45)   
Serious Adverse Device Effect 
(SADE)  Adverse device effect that has resulted in any of the consequences characteristic of a 
serious adverse event.  
(ISO [ZIP_CODE]:2020, 3.44)   
 
12.5.  Reporting of Adverse Events  
12.5.1 Adverse Event and Device Deficiency Classification  
All AE and DD will be reviewed by a Medtronic representative. AEs will be classified according to the 
definitions provided.  
Upon receipt of AE at Medtronic, a Medtronic representative will review the AE/DD for completeness and 
accuracy and when necessary will request clarification and/or additional information from the 
Investigator. Medtronic will utilize MedDRA for Regulatory Activities, to assign a MedDRA term for each 
AE based on the information provided by [CONTACT_737].  
Regulatory reporting of AEs and DDs will be completed according to local regulatory requirements. Refer 
to Table  [ADDRESS_278211] regarding a UADE, [LOCATION_003]DE, SAE and/or SADE, contact a study representative 
immediately (refer to the study contact [CONTACT_230997]’s study documents 
binder/investigator site file or refer to the Sponsor contact [CONTACT_131484]).  
AEs and Deaths will be classified according to the standard definitions as outlined below:  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 58 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
   
Table 6: Adverse Event Classification Responsibilities  
What is classified?  Who classi fies?  Classification Parameters  
Relatedness  Investigator  Device, Procedure   
Sponsor  Device, Procedure  
Seriousness  Investigator  SAE, DD with SADE potential  
Sponsor  SAE, UADE/[LOCATION_003]DE, Complication or Observation (for all system or 
procedure related adverse events), DD with SADE potential  
Diagnosis  Investigator  Based on presenting signs and symptoms and other supporting data  
Sponsor  MedDRA t erm assigned based on the data provided by [CONTACT_10670]  
12.5.2 Adverse Event and Device Deficiency Reporting Requirements  
Regulatory reporting of AEs and DDs will be recorded and reported according to local regulatory 
requirements. It is the responsibility of the Investigator and the sponsor to abide by [CONTACT_230998]’ s IRB.  
Table 7: Reporting Requirements   
Serious Adverse Device Effects (SADE), including Unanticipated Adverse Device Effect (UADE):  
Investigator submits  to:  
Medtronic  Within [ADDRESS_278212] learns of the event . 
Regulatory Authority  As per local reporting requirement s.  
IRB Submit to IRB  per local reporting requirement.  
Sponsor submit s to:  
Regulatory Authorities  Reporting timeframe as per local requirement.  
IRB Submit to IRB  per local reporting requirement.  
Serious Adverse Events (SAE)  
Investigator submits  to:  
Medtronic  Within [ADDRESS_278213] learns of the event . 
Regulatory Authority  As per local reporting requirement s.  
IRB  Submit to IRB  per local reporting requirement.  
Sponsor submit s to:  
Regulatory Authorities  Reporting timeframe as per local requirement.  
IRB  Submit to IRB  per local reporting requirement.  
Adverse Device Effects (ADE)  
Investigator submits to:  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278214] learns of the event . 
Sponsor submit s to:  
Regulatory Authority  As per local reporting requirement s.  
IRB  Submit to IRB  per local reporting requirement.  
Sponsor submit s to:  
Regulatory Authorities  Reporting timeframe as per local requirement  
IRB  Submit to IRB  per local reporting requirement.  
All other AEs  
Investigator submits  to:  
Medtronic  Submit as soon as possible, but no later than within [ADDRESS_278215] learns of the event . 
Regulatory Authority  As per local reporting.  
IRB  Submit to IRB  per local reporting requirement.  
Device Deficiency with SADE potential  
Investigator submits  to:  
Medtronic  No later than [ADDRESS_278216] learns of the event.  
Regulatory Authorities  As per local reporting requirement s. 
IRB  As per local reporting requirement.  
Sponsor submit s to:  
Regulatory Authorities  As per local reporting requirement s. 
IRB  As per local reporting requirement.  
All other Device Deficiencies  
Investigator submits  to  
Medtronic  No later than [ADDRESS_278217] learns of the event.  
Regulatory Authorities  As per local reporting requirement s. 
IRB  As per local reporting requirement.  
Sponsor submit s to:  
Regulatory Authorities  As per local reporting requirement s. 
IRB  As per local reporting requirement.  
 
Study Contact [CONTACT_7171]: 
Clinical Affairs  Medical Affairs  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278218]  
Boulder, CO [ZIP_CODE] 
Phone: ( 801)  793-4800 
ami.stuart @medtronic.com  Sam Ajizian , MD  
Chief Medical Officer- Patient Monitoring  
Medtronic  
350 Cedar Trail  
Winston -Salem, NC  [ZIP_CODE]  
Phone:  ([PHONE_4855]  
sam.a jizian @medtronic.com  
 
12.[ADDRESS_278219] Complaint: Any written, electronic or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness or performance of a medical device that has been placed on the market.  
 It is the responsibility of the investigator to report all product complaint(s) associated with a medical 
device distributed by [CONTACT_13735], regardless whether they are related to intended use, misuse or abuse of 
the product. Reporting must be done immediately and via the regular channels for market -released 
products. The reporting of product complaints by [CONTACT_230999]. Medtronic will notify the RAs (e.g. CA) as applicable for the following 
incidents immediately upon learning of them and is not limited to AEs and DDs only:  
• Any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labeling or instructions for use which led or might have led to the 
death or serious deterioration in the state of health of a patient, user, or other person.  
• Any technical or medical reason resulting in withdrawal of a  device from the market by [CONTACT_13989].  
• Any serious deterioration in the state of health, including:  
o Life-threatening illness or injury  
o Permanent impairment of a body function or permanent damage to a body structure  
o A condition necessitating medical o r surgical intervention to prevent permanent impairment 
of a body function or permanent damage to a body structure  
13. Data Review Committees  
Neither a Data Monitoring Committee (DMC)  nor an  Adverse Events Advisory Committee (AEAC) will be  
utilized for this c linical study as there are no safety concerns suggesting the need for a DMC. This study  is 
considered a non -significant risk for study participants. Thus, the need for additional safety oversight  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 61 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  beyond Medtronic’s already rigorous safety monitoring proces ses is not required.  A Medtronic Medical 
Advisor , as needed , will provide an independent medical review according to the study Safety and 
Complaint  Management Plan. The Medical Advisor will not be affiliated with an investigative center.  
14. Statistical Design and Methods  
The s tatistical analyses will be conducted  by [CONTACT_231000] (SAP.) Any changes in statistical methods will be detailed  in the Clinical Study Report (CSR) 
Data exclusion will be captured in the Data Management Plan.    
 
 
14.1.  Sample Size Justification  
A two -stage adaptive design is used in this study. For each regimen, 10 subjects will be enrolled in stage 
1, and upon evaluat ion, up to 20 additional subjects will be enrolled in stage 2. With 5  regimens, a 
maximum of 150 subjects will be expected. Based on the dose- response  relationship (logistic  model ) with 
an allowable error of ± 15% for BIS 50 and a coefficient of variation of 25% at the alpha level of 0.05, the 
sample size will provide sufficient power (>80%) to evaluate the performance of anesthetic agents.  
 
14.2.  Analysis Populations  
All randomized subjects will be included in the analysis. For those su bjects who do not complete a follow -
up call, the analysis will include all data up to the last collected point or follow -up call.  Subjects who 
completed the procedure phase will not be replaced. If the subject discontinues prior to randomization  
or during the procedure phase, she/he will be replaced , but will count toward the total sample size if they 
were randomized . 
 
14.3.  Statistical  Methods  
Standard demographic information and baseline characteristics will be summarized using descriptive 
statistics.  
 
For safe ty assessments, adverse events (AEs) will be summarized using frequency counts and percentages. 
Descriptive statistics will be provided by [CONTACT_231001] .  
 
Any subject who responds to any verbal command with MOAA/S assessment score s of 2, 3, 4, and 5 will 
be considered as responsive. Subjects with MOAA/S assessment score s of 0  and 1 will be considered 
unresponsive. Tetanic Electrical Stimulation (TES) will be employed with an MOAA/S assessment score of 
≤[ADDRESS_278220] two subjects in each group and <2 for all other subjects.  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 62 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
   
The BIS ™ index value collected from the left side of the brain will be used for primary analysis to reflect 
the typi[INVESTIGATOR_230934]. The BIS ™ index value collected  from the right side of 
the brain will be used for internal research  purposes .  
 
The logistic model (simplified Sigmoid Emax model ) will be used to analyze the relationship between the 
BIS™ index and loss of responsiveness  through the probability of response curves. The value s of BIS ™ at 
which 50% (BIS 50) and 95% (BIS 95) of subjects are unresponsive , and the ir 95% confidential intervals  will 
be derived.  The systematic variance between groups will be evaluated. The Prediction Probability  score 
(Pk) for correctly predicting if the subject was responsive or unresponsive will be assessed.   
 
14.4.  Interim  Review  
The interim  review  will be performed at the end of stage 1 , when all ( 50 subjects 10 subjects per regimen  
group ) subjects have completed the evaluation. BIS ™ values will be estimated using the Hill equation. One 
or more regimens may be dropped upon interim results for safety concern s (unacceptable safety events 
per clinical judgment).     
 
For the final analysis, data from stage 1 and stage 2 will be combined by [CONTACT_231002] -
ability across sites and the adaptive nature of the 2 -stage design  (e.g., Bayesian integration with power 
prior and discounting function) . Technical details will be specified in the SAP.   
15. Ethics 
 
15.1. Statement(s) of Compliance  
The investigator is responsible for ensuring that the clinical study is conducted  in accordance with : 
• The Declaration of Helsinki (2013) and local laws and regulations of the countries in which the 
clinical study is conducted, including data protection laws, the Clinical Trial Agreement, Good 
Clinical Practice (GCP)  E6 and regulatory requirement(s), including 21  CFR 803, 21 CFR 812.2, 21 
CFR 50, 21 CFR 56. FDA Financial Disclosure regulations , 21 CFR 54,  and th is Clin ical Investigational 
Plan.  
• All principles of the Declaration of Helsinki have been implemented in this clinical study by [CONTACT_231003], IRB  approval, clinical study training.  
• Investigators must inform Medtronic of any change in the status of IRB  approval once the 
investigation site has started enrollment. If any action is taken by [CONTACT_231004], that information will be forwarded to Medtronic by [CONTACT_231005].  
• The clinical study will not begin  until the IRB or regulatory authority (if applicable) approval/ 
notification is received . Written IRB  approval and any conditions of approval imposed by [CONTACT_231006].   
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 63 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • If the IRB  or other regulatory authorit ies impose any additional requirements (e.g., safety reports, 
progress reports, etc.), Medtronic will prepare the required documents and send them to the 
respective authority.  
16. Study Administration  
 
16.1.  Monitoring  
Site monitoring visits will be performed by [CONTACT_231007]:  
• Overall compliance with the protocol, GCP,  and the applicable regulations.  
• Accurate records are being maintained.   
• Accurate  and complete study data are being reported  (comparing CRF to source documents.) 
In some cases, the CRF will also be the source documentation of some information.  
• Informed consent has been obtained  for all study subjects.  
• Adverse events and protocol deviations are documented  and reported.  
• Investigational and non -investigational device accountability and disposition are accurately 
documented.  
Monitoring visits will be conducted at the start, during, and at the closure of th e clinical study in 
accordance with Medtronic SOPs and the Monitoring Plan.  An interim monitoring visit may be combined  
with the closing monitoring visit.  
 
The frequency  of monitoring visits will occur based on subject enrollment, duration of the study, study 
compliance, site performance, site adherence to the protocol, findings from previous monitoring visits, 
and any suspected inconsistency in data that requires investi gation. The monitoring visit frequency may 
be changed based on study needs and subject enrollment rates.  Specific monitoring requirements are 
detailed in the study -specific Monitoring Plan.  
 
The Sponsor will provide updated contact [CONTACT_142821], including the mon itors’ name [CONTACT_3669] [CONTACT_231008].  
 Monitoring activities will be documented and include a summary of what the monitor reviewed and the observations regarding the completion of previous action items, significant findings, facts, deviations, 
conclusions, and recommended actions to be taken to secure compliance.  
If problems are encountered  with the quality of the collected data, the study may  be halted for the period 
of time  until the problem has been assessed  and corrected . The evaluation of the data quality will be the 
responsibility of the Medtronic Clinical Affairs personnel or designee.  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278221] be provided to the study s ponsor  and authorized 
sponsor’s representatives , regulatory authorities, auditors, IRB members , or inspectors.  
 
Direct access to patient medical files for source data verification will need to be granted and pr epared 
prior to any monitoring visits.  
 Raw  device data will not be monitored . 
 
16.2.  Data Management  
The investigator must ensure accuracy, completeness, and timeliness of the data reported in the eCRFs 
and all other required reports. Data reported on the eCRFs which are derived from source documents 
must be consistent with the source documents, and discrepancies need to be justified in a documented 
rationale, signed and dated by [CONTACT_941] (principal) investigator, and filed in the patient medical file.  
 
Only aut horized persons can complete eCRFs. All data requested on the eCRF are considered required. 
The Principal Investigator [INVESTIGATOR_230935]/her signature [CONTACT_231034]. The Investiga tor’s electronic signature [CONTACT_231035]. Changes to data previously submitted to the sponsor will require a new electronic signature [CONTACT_3265] [CONTACT_197086]/approve the 
changes.  
 
Medt ronic will only consider eCRFs to be complete when all discrepancies have been resolved by [CONTACT_231009]. Also, specific eCRFs must be reviewed and electronically signed 
by [CONTACT_737], indicating his/her agreement with  the accuracy of all recorded data. It is expected 
that the Investigator and his/her staff will cooperate with the monitoring team and provide any missing 
data in a timely manner.  
 
The Electronic Data Capture (EDC) system maintains an audit trail on entries, changes, or corrections in 
eCRFs. Upon completion of a CRF, the investigator shall sign the eCRF in a timely manner, if a change to 
an already signed eCRF occurs, the investigato r shall re -sign this eCRF . 
 
16.3.  Direct Access to Source Data/Documents  
The principal investigator(s), his/her delegate(s), and the study coordinator(s) shall be accessible to 
Medtronic field personnel and the Clinical Study Manager. This accessibility is of particular importance for 
reviewing data on the electronic Case Report Form (eCRF). Direct or remote access to subject medical files 
for source data verification will need to be granted and prepared prior to any monitoring visits.   
 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278222] confidentiality according to local and national regulations 
and institutional requirements.  
 
16.5.  Liability  
Medtronic maintains appropriate clinical study liability insurance coverage as required under applicable 
laws and regulations and will comply with applicable local law and custom concerning specific insurance 
coverage. If required, a clinical study insurance statement/certificate will be provided to the IRB.  
 
16.6.  CIP Amendments  
The investigator may propose any appropriate modification(s) to the Clinical Investigation Plan or 
investigational device or investigational device use. Medtronic will review and decide whether the 
modification(s) will be implemented . 
 
Medtronic will submit any amendment to the Clinical Investigation Plan, including a justification for such 
amendment, to the investigators to obtain approval from their IRB.  
 
Any amendment to the protocol requires written approval by [CONTACT_231010] (if 
appli cable) prior to  its implementation  unless there are overriding safety reasons. In some instances, an 
amendment may require a change to the ICF.  
 
The Sponsor and Investigator will obtain IRB approval concerning the revised ICF prior to  the 
implementation o f the change. The Investigator understands that subjects must be consented using the 
most current IRB approved  version of the ICF. If the ICF is updated, subjects who have participated will be 
re-consented at the direction of the IRB.  
 
16.7.  Record Retention  
16.7.1  Investigator Records  
The investigator is responsible for the preparation and retention of the records cited below. All of the 
below records, with the exception of case history records and case report forms, should be kept in the 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 66 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  Investigator Site File (i.e., the study binder provided to the investigator) or Subject Study Binder. CRFs 
must be maintained and signed electronically within the electronic data capture system during the study. 
The following records are subject to inspection and must be retained for a  period of two years (or longer 
as local law or hospi[INVESTIGATOR_54387]) after product approval or the date on which the 
investigation is terminated.  
• All correspondence between the IRB , sponsor, monitor, RA and the investigator that pertains to 
the investigation, including required reports.  
• Subject’s case history records, including:  
o Signed and dated IC F  
o Observations of AEs/ADEs/DDs  
o Medical history  
o Documentation of the dates and ratio nale for any deviation from the protocol  
• Randomization list  
• List of investigation study sites  
• Financial Disclosure ( FD)  
• Subject screening log & ID log  
• Normal value(s)/range(s) for clinical laboratory test (if applicable)  
• Lab certificate  
• Device Dispositi on Logs containing Model and serial numbers of devices delivered to the  study 
site, subject IDs of the subjects implanted, received dates of devices, implant/used dates, explant dates, returned -to-sponsor dates and reasons, initials of all persons who rec eived, used or 
disposed each device, and method of disposal/destruction.  
• All approved versions of the CIP, IC F  
• Signed and dated CTA.  
• CV of principal investigators and key members of investigation study site team (as required by [CONTACT_5279].  
• Documentation of delegated tasks.  
• IRB approval documentation. Written information that the investigator or other study staff, when 
member of the IRB, did not participate in the approval process. Approval documentation must 
include the IRB s composition, where required per local law.   
• Regulatory Authority (RA)  notification, correspondence and approval, where required per local 
law. 
• Study training records for study site staff.  
• Any other records that FDA and local regulatory agencies require to be maintained.  
• Final Study Report including the statistical analysis.  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 67 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  16.7.2  Sponsor Records  
Medtronic shall maintain the following accurate, complete, and current rec ords:  
• All correspondence which pertains to the investigation  
• Investigational device traceability record containing Model and serial numbers of devices, shippi[INVESTIGATOR_230936], location (if different than 
person shipped to), transfer and receipt by [CONTACT_231011]  
• Sample of label attached to investigational device  
• Signed Investigator Trial Agreements, FD and current signed CV of principal investigator [INVESTIGATOR_230937] (as required by [CONTACT_1769]), delegated task list  
• All signed and d ated case report forms submitted by [CONTACT_1697], including reports of AEs, ADEs 
and DDs  
• All approved IC F templates, and other information provided to the subjects and advertisements, 
including translations  
• Randomization records  
• Copi[INVESTIGATOR_230938]/roster/letter 
of assurance  
• Names of the institutions in which the study will be conducted  
• RA correspondence, notification and approval as required by [CONTACT_54458]  
• Names/contact [CONTACT_54459]  
• Monitoring visit reports  
• Statistical analyses and underlying supporting data  
• Final report of the study  
• The CIP, IB/Report of Prior Investigations summary and study related reports, and revisions  
• Study training records for study site personnel a nd Medtronic personnel involved in the study  
• Any other records that local regulatory agencies require to be maintained.  
 
Medtronic records and reports will be maintained in a password -protected document management 
system, and paper documents (where applic able) will be stored in stored in secured file cabinets at 
Medtronic during the course of this study.  
After closure of the study Medtronic could archive records and reports indefinitely.  
 
16.8.  Reporting Requirements  
Investigator Reports  
The investigator is responsible for the preparation (review and signature) and submission to the sponsor 
of all case rep ort forms, adverse events and adverse device effects (reported per the country -specific 
collection requirements), device deficiencies, death s, and any deviations from the clinical investigation 
plan.  If any action is taken by [CONTACT_231012], copi[INVESTIGATOR_230939] ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278223] to inspection and to the 
retention requirements as described above for investigator records.  
Safety data investigator reporting requirements are listed in Section  12. The investigator shall prepare and 
submit in a complete, accurate and timely manner the reports listed in this section.  
 
Table 8 : Investigator reports applicable for all geographies per Medtronic requirements  
Report  Submit to  Description/Constraints  
UADE  Sponsor  An investigator shall submit to the sponsor and to the reviewing IRB a report of 
any UADE occurring during an investigation as soon as possible, but in no event 
later than [ADDRESS_278224]. (21 CFR 
812.150(a))  
Withdrawal of IRB approval  Sponsor and Relevant 
Authorities  The investigator must report a withdrawal of approval by [CONTACT_231013]’s part of the investigation within [ADDRESS_278225] be submitted within  12 months of study completion or 
termination.  
Sponsor Reports  
Medtronic shall prepare and submit the following complete, accurate, and timely reports (by [CONTACT_13736]).  
Medtronic shall, upon request of the reviewing IRB, RA or FDA, provide accurate, complete and current 
information about any aspect of the investigation. Safety data Me dtronic reporting requirements are 
listed in Section  12.  
 
 
16.9.  Publication and Use of Information  
The Medtronic Publication and Authorship Policy is aligned with the International Committee of Medical  
Journal Editors (ICMJE) recommendations (www.icmje.org). The Sponsor will seek to publish, in  
appropriate peer- reviewed journals and scientific conferences, results of clinical studies where human  
subjects are involved, regardless of the outcome. The study will be recorded on www.clinicaltrials.gov  
before the first enrollment.  
 
While study results are owned by [CONTACT_1034], all data on  which a publication is based will be made  
available to all authors as required for their participation  in the publication processes. Furthermore,  data 
may be published or used by [CONTACT_231014], the Medtronic Publication and  Authorship Policy, and the Clinical Investigation 
Agre ement. Investigators must submit a copy of all manuscripts and/or abstracts to the Sponsor for review 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 69 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  and comment 30 days prior to planned  submission. Medtronic acknowledges that its right to review and 
comment shall relate solely to the proprietary, licen sing, and/or confidential rights Medtronic may have 
in such proposed publication,  rather than whether such results and/or opi[INVESTIGATOR_230940].  
 
The number of authors will be dependent on the regulations of the concerning journal. Authorship  on any 
publication(s) resulting from this clinical study will be assigned according to substantial contributions to 
conception and design, acquisition of data, or analysis and interpretation of data,  drafting the article or 
revising it critically for rele vant intellectual content and final approval of the  version to be published. 
Names of all participating investigators will appear in the Acknowledgment of the paper.  
 
The publication of sub -studies, post -hoc analyses, regional results, or single -center experiences based on  
multicenter clinical studies should not precede that of the primary multicenter publication and should  cite 
the primary publication whenever possible, as required by [CONTACT_231015].  
 Medtronic involvement in a publication (e.g., funding of the study; sponsor of the study; collection,  
analysis, and interpretation of data; professional writing assistance) must be disclosed according to  
journal -specific policies, submission requirements, and prevailing editorial standards, in addition to  those 
specified by [CONTACT_231016]. The a uthors must ensure that an  
acknowledgment/disclosure statement is included in the body of the manuscript for Medtronic to  review 
for accuracy. All authors must also disclose financial or personal affiliations that could be  considered 
conflicts of interest as per journal/conference requirements.  
 
Medtronic , as the owner of the data , can use the data and/or any results derived from th e data or 
publications based on that data for marketing purposes, further research , and development of devices or 
educational use. The study sponsor will collect data in such a way that no subject can be identified and 
monitor study records. Participating subjects will not be identified by [CONTACT_231017].  
 
16.10.  Suspension or Early Termination  
The Sponsor reserves the right to discontinue the study at any stage, with written notice to all investigators, all reviewing IRBs. Similarly, investigators may withdraw from the study at any time, subject 
to providing written notification to the Sponsor 30 days prior to the date they intend to withdraw.  
The Sponsor and investigators will be bound by [CONTACT_231018] f ollow -up of subjects 
already participating in the study. If the study is terminated or suspended, no additional enrollment will be allowed unless otherwise informed by [CONTACT_456]. The current subjects will be followed  according to 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278226] follow -up shall be reported to the Sponsor on the 
appropriate eCRF. 
 
If the study is terminated prematurely or suspended by [CONTACT_456], the sponsor will promptly inform the 
investigators and regulatory authorities (if require d) of the termination and the reason(s). The IRB will 
also be promptly informed and provided with the reason(s) for termination or suspension by [CONTACT_231019]. The investigator will promptly inform the subjects and assure appropriate t herapy 
and follow -up for the subject, as needed.  
 
If the investigator (or IRB ) terminates or suspends the investigation without the prior  agreement of the 
sponsor, the investigator will promptly inform the sponsor, the institution (if required) , and the IRB  and 
provide a detailed written explanation of the termination or suspension. The sponsor will inform the 
regulatory authorities (if req uired.)  
 
Medtronic reserves the right to discontinue the study at any time for administrative or other reasons. 
Written notice of study termination will be submitted  to the investigator in advance of such termination. 
Possible reasons for considering study  suspension or termination of the study for all centers include but 
are not limited to:  
• Failure to obtain initial IRB  approval or annual renewal of the study  
• Consistent non -compliance to the CIP (e.g. , failure to adhere to inclusion/exclusion criteria, 
failure to follow subjects per scheduled follow -ups, failure to implement required corrective 
and preventive actions, etc.)  
• Lack of enrollment  
• Noncompliance to regulations and the terms of the Clinical Trial Agreement (e.g. , failure to 
submit data in a timely  manner, failure to follow -up on data queries and monitoring findings 
in a timely manner, etc.)  
• IRB suspension of the center  
• Fraud or fraudulent misconduct (as defined by [CONTACT_54468])  
• Investigator request (e.g. , no longer able to support the study)  
17. References  
1. Minto, C.F., T.W. Schnider, and S.L. Shafer, Pharmacokinetics and Pharmacodynamics of 
Remifentanil: II. Model Application.  Anesthesiology 1997. 86: p. 24- 33. 
2. Iwakiri, H., et al., Effect -Site Concentration of Propofol for Recovery of Consciousness Is Virtually 
Independent of Fentanyl Effect -Site Concentration.  Anesth Analg, 2003. 96 : p. 1651- 5. 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 71 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  3. Alkire, M.T., A.G. Hudetz, and G. Tononi, Consciousness and Anesthesia.  Science, 2008. 322 : p. 
876-880.  
4. Rampil, I.J., A Primer for EEG Signal Processing in Anesthesia.  Anesthesiology, 1998. 98 (4): p. 
980-1002.  
5. Clark, D.L. and B.S. Rosner, Neurophysiologic effects of general anesthetics. I. The 
electroencephalogram and s ensory evoked responses in man.  Anesthesiology, 1973. 36(6): p. 
564-582.  
6. Akeju, O., et al., Effects of Sevoflurane and Propofol on Frontal Electroencephalogram Power and 
Coherence.  Anesthesiology, 2014. 121 (5): p. 990- 998.  
7. Secretariat, M.A., Bispectr al index monitor: an evidence based analysis. , O.H.T.A. Series, Editor. 
2004.  
8. Gan, T.J., P.S. Glass, and A. Windsor, Bispectral index monitoring allows faster emergence and improved recovery from propofol, alfentanil, and nitrous oxide anesthesia. BIS U tility Study 
Group.  Anesthesiology, 1997. 87(4): p. 808 -815.  
9. Glass, P.S., et al., Bispectral Analysis Measures Sedation and Memory Effects of Propofol, 
Midazolam, Isoflurane, and Alfentanil in Healthy Volunteers.  Anesthesiology, 1997. 86 (4): p. 836 -
847.  
10. Aho, A.J., et al., Comparison of Bispectral Index and Entropy values with electroencephalogram during surgical anaesthesia with sevoflurane.  Br J Anaesth, 2015. 115(2): p. [ADDRESS_278227] of bispectral index for monitoring propo fol remifentanil anaesthesia. A 
randomised clinical trial.  Acta Anaesthesiol Scand, 2013. 57 (8): p. 978 -87. 
12. Bresson, J., et al., A Randomized Controlled Trial Comparison of NeuroSENSE and Bispectral Brain Monitors During Propofol -Based Versus Sevoflurane -Based General Anesthesia.  Anesth Analg, 
2015. 121(5): p. 1194 -201.  
13. Brown, C.H.t., et al., Sedation depth during spi[INVESTIGATOR_230941].  Anesth Analg, 2014. 118 (5): p. 977 -80. 
14. Chan, M.T.V ., et al., BIS -guided Anesthesia Decreases Postoperative  Delirium and Cognitive 
Decline.  J Neurosurg Anesthesiol, 2013. 25 : p. 33- 42. 
15. Cheung, Y.M., et al., Evaluation of the aepEX monitor of hypnotic depth in pediatric patients 
receiving propofol -remif entanil anesthesia.  Paediatr Anaesth, 2013. 23 (10): p. 891 -7. 
16. Cheung, Y.M., et al., Evaluation of the auditory evoked potentials derived aepEX() as a measure 
of hypnotic depth in pediatric patients receiving sevoflurane -remifentanil anesthesia.  Paediat r 
Anaesth, 2014. 24(7): p. 760 -5. 
17. Conte, V., et al., Bispectral Index During Asleep- Awake Craniotomies. J Neurosurg Anesthesiol, 
2013(25): p. 279- 284.  
18. Frederick, H.J., et al., A Randomized Controlled Trial to Determine the Effect of Depth of Anesth esia on Emergence Agitation in Children.  Anesth Analg, 2016. 122(4): p. 1141- 6. 
19. Fritz, B.A., H.R. Maybrier, and M.S. Avidan, Intraoperative electroencephalogram suppression at lower volatile anaesthetic concentrations predicts postoperative delirium occurring in the intensive care unit.  Br J Anaesth, 2018. 121(1): p. 241 -248.  
20. Fritz, B.A., et al., ostoperative Recovery with Bispectral Index versus Anesthetic Concentration-guided Protocols.  ASA publications Anesthesiology 2013. 118 (5): p. 1113.  
21. Jindal, A., et al., Bispectral index monitoring for diagnosis and assessment of severity of hepatic encephalopathy in cirrhotic patients.  Dig Liver Dis, 2015. 47 (9): p. 769 -74. 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 72 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  22. Jung, J.Y., C.B . Cho, and B.M. Min, Bispectral index monitoring correlates with the level of 
consciousness in brain injured patients.  Korean J Anesthesiol, 2013. 64 (3): p. 246 -50. 
23. Kertai, M.D., W.D. White, and T.J. Gan, Cumulative Duration of “Triple Low” State of Lo w Blood 
Pressure, Low Bispectral Index, and Low Minimum Alveolar Concentration of Volatile Anesthesia 
Is Not Associated with Increased Mortality.  Anesthesiology, 2014(121): p. 18- 28. 
24. Lee, S.Y., et al., Comparison of bispectral index scores from the standard frontal sensor position 
with those from an alternative mandibular position.  Korean J Anesthesiol, 2014. 66(4): p. 267 -73. 
25. Liu, P.P., et al., The prediction probabilities for emergence from sevoflurane anesthesia in 
children: A comparison of the perfusion index and the bispectral index.  Paediatr Anaesth, 2018. 
28(3): p. 281 -286.  
26. Mei, B., et al., Peripheral Nerve Block as a Supplement to Light or Deep General Anesthesia in 
Elderly Patients Receiving Total Hip Arthroplasty: A P rospective Randomized Study.  Clin J Pain, 
2017. 33(12): p. 1053 -1059.  
27. Nitzschke, R., et al., Bispectral index guided titration of sevoflurane in on- pump cardiac surgery 
reduces plasma sevoflurane concentration and vasopressor requirements: a prospectiv e, 
controlled, sequential two -arm clinical study.  Eur J Anaesthesiol, 2014. 31 (9): p. 482 -90. 
28. Orliaguet, G.A., et al., Feasibility of Closed -loop Titration of Propofol and Remifentanil Guided by 
[CONTACT_231020].  Anesthesiology. 122: p. 759- 767.  
29. Schuller, P.J., et al., Response of bispectral index to neuromuscular block in awake volunteers.  Br 
J Anaesth, 2015. [ADDRESS_278228] 1 : p. i95- i103.  
30. Sciusco, A., et al., Effect of age on the performance of bispectral and entropy indices during 
sevoflurane pediatric anesthesia: a pharmacometric study.  Paediatr Anaesth, 2017. 27(4): p. 
399-408.  
31. Shan, K., et al., Use of the critical- care pain observation tool and the bispectral index for the 
detection of pain in brain- injured patients undergoing mechanical ventilation: A STROBE -
compliant observational study.  Medicine (Baltimore), 2018. 97 (22): p. e10985.  
32. Shanks, A.M., et al., Alerting thresholds for the prevention of intraoperative awareness with 
explicit recall: a secondary analysis of the Michigan Awareness Control Study.  Eur J Anaesthesiol, 
2015. 32(5): p. 346- 53. 
33. Short, T.G., et al., Refining Target -Controlled Infusion: An Assessment of Pharmacodynamic 
Target -Controlled Infusion of Propofol and Remifentanil Using a Response Surface Model of Their 
Combined Effects on Bispectral Index.  Anesth Analg, 2016. 122(1): p. 90- 7. 
34. Shoushtarian, M., et al., Comparisons of Electroencephalographically Derived Measures of Hypnosis and Antinociception in Response to Standardized Stimuli During Target -Controlled 
Propofol -Remifentanil Anesthesia.  Anesth Analg, 2016. 122(2): p. 382 -92. 
35. Subramani, Y., et al., Optimal propofol induction dose in morbidly obese patients: A randomized controlled trial comparing the bispectral  index and lean body weight scalar.  Can J Anaesth, 2017. 
64(5): p. 471 -479.  
36. Tschiedel, E., et al., Sedation monitoring during open muscle biopsy in children by [CONTACT_231021] -  a prospective analysis.  Paediatr Anaesth, 2015. 25(3): p. 265 -71. 
37. Vance, J.L., A.M. Shanks, and D.T. Woodrum, Intraoperative bispectral index monitoring and time to extubation after cardiac surgery: secondary analysis of a randomized controlled trial.  
BMC Anesthesiology, 2014. 14(79): p. 1 -7. 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.[ADDRESS_278229] -track cardiac surgery.  Anesth Analg, 
2013. 116(3): p. [ADDRESS_278230] Deep Sedation in Mechanically Ventilated 
Patients: A Prospective Multicenter Validation Study.  Anesth Analg, 2017. 125(1): p. 176 -183.  
40. Whitlock, E.L., et al., Postoperative delirium in a substudy of cardiothoracic surgical patients in 
the B AG-RECALL clinical trial.  Anesth Analg, 2014. 118(4): p. 809 -17. 
41. Willingham, M.D., et al., Concurrence of Intraoperative Hypotension, Low Minimum Alveolar 
Concentration, and Low Bispectral Index Is Associated with Postoperative Death.  Anesthesiology, 
2015(123): p. 00- 85. 
42. Soehle, M., et al., Bilateral bispectral index monitoring during and after electroconvulsive 
therapy compared with magnetic seizure therapy for treatment -resistant depression.  Br J 
Anaesth, 2014. 112(4): p. 695 -702.  
43. Dahaba, A.A., et al., Different Propofol– Remifentanil or Sevoflurane –Remifentanil Bispectral 
Index Levels for Electrocorticographic Spi[INVESTIGATOR_230942].  
Anesthesiology, 2013. 119 : p. 582 -592.  
44. Nimmo, A.F., et al., Guidelines for the safe pr actice of total intravenous anaesthesia (TIVA).  
Anaesthesia, 2019. 74 : p. [ADDRESS_278231] -site concentration of remifentanil when combined with 
dexmedetomidine in patients undergoing cystoscopy.  Korean J Anesthesiol, 2014. 66 (1): p. 39-
43. 
46. Minto, C.F., et al., Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development.  Anesthesiology, 1997. 86 : p. 10 -23. 
47. Chernik, D.A., et al., Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: study with intravenous midazolam.  J Clin Psychopharmacol, 1990. 10 (4): p. 244 -51. 
48. Krudi, B., et al., Introducing the Open Affectve Standardized Image Set (OASIS). Behav Res, 2017. 
49: p. 457- 470  
 
 
 
18. Appendices  
Appendix A -  Modified Observer's Assessment of Alertness/Sedation scale  
 
The Observer Assessment of Alertness/Sedation (OAA/S) Scale  [47] 
Response  Score  
Responds readily to name [CONTACT_154992]  5 
Responds lethargically to name [CONTACT_154992]  4 
Responds only after name [CONTACT_231036], repeatedly, or both  3 
Responds only after mild prodding or shaking  2 
Responds only after painful trapezius squeeze  1 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 74 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  Does not respond to painful trapezius squeeze  0 
 
Appendix B –  Open Affective Standardized Image Set (OASIS)  
 
Pi[INVESTIGATOR_230943].  
 
Appendix C –  NCM Sub- Study – Non -Contact [CONTACT_231022]- Sensing Respi[INVESTIGATOR_230944]19053OLIVER  Study (Main Study) may be invited to participate in the product 
development sub -part of the study. The purpose of this non -contact [CONTACT_231023] -study (N CM Sub -
Study) is to collect data for further exploration of a non -contact [CONTACT_231024] -sensing camera technology.  
 
Medtronic is continuously improving its monitoring devices  to improve performance and widen the range 
of capabilities.  In order to  develop and assess a newly developed technology, the NCM Sub -Study is 
executed to collect data to show early feasibility and proof of concept for novel non-contact [CONTACT_231025].  
 
Background 
Recently, Medtronic has worked on depth -sensing technologies where the distance from the camera to 
objects within the field of view is captured and used to produce physiological information, including 
airway resistance, heart rate, respi[INVESTIGATOR_697], volume change, and apnea event s. Depth sensing cameras 
produce grayscale images where the intensity of pi[INVESTIGATOR_230945]. 
Color mappi[INVESTIGATOR_230946], an example of which is contained in Figure 5.  
 
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 75 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
   
Figure  5: A false color depth image where a subject can be identified. A light blue mask indicates the torso region of interest 
(ROI) from where the volume change signal is computed. The volume change signal is shown in th e lower part of the figure.  
 
From this image, we have developed a technology to automatically superimpose a mask on the torso of 
the subject (as shown in Figure 5 ) from which we can measure distances from the camera over time. By 
[CONTACT_231026] (ROI) over time, we can provide a 
real- time estimate of tidal volume change as the lungs expand and contract during i nhalation and 
exhalation, respectively. An example of this calculated volume change signal is shown at the bottom of 
Figure 5 . The volume change signal can then be converted to a tidal volume per breath and a respi[INVESTIGATOR_862] (and hence minute volume).  
 
From the volume change signal, we can extract a variety of physiological parameters, including tidal 
volume (peak -to-trough amplitude of the volume change signal), respi[INVESTIGATOR_697] (frequency of volume 
change signal modulations), individual breath period and corresponding inhalation/exhalation (I/E) ratio, 
minute volume, etc. We can also extract a volume change signal from the chest and abdomen regions 
separately from which an indication of out of phase breathing, indicative of obstructive apnea, can be 
derived (as shown in Figure 6 ). The technology also  detects cessation of breathing, talking, and coughing.  

Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 76 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
   
Figure 6: Paradoxical breathing shown on a subject’s torso. Green indicates regions where the subject torso is moving 
towards the camera. Red indicates regions where the subject torso is moving awa y from the camera. Yellow/black indicates 
non- moving regions.   
 
Objective  
To collect depth -sensing video and respi[INVESTIGATOR_230947] -
contact [CONTACT_15206][INVESTIGATOR_230948].  
 
 
 
Product Description  
The RealSense D415 depth camera system (manufactured by [CONTACT_231027]™) is a non -contact [CONTACT_231028] a scene using infrared sensing technology. It is a consumer product 
developed by [CONTACT_231027]™. Other commercially available depth -sensing systems may be employed in the study, 
(for example, th e Microsoft ™ Kinect Azure or Microsoft ™ Kinect V2, INTEL RealSense D435, INTEL™ 
RealSense L515, Stereolabs™ ZED depth -sensing cameras or similar) . Cameras may be used off- the-shelf, 
and no modifications to the actual product are required.  
 
Study Visit (Ma in Study Visit 2 ) 
For the subject who enrolled in the main study and consented to participate in NCM Sub -Study:  
• Non -contact [CONTACT_10056] (NCM) camera will be placed 1.0 –  2.[ADDRESS_278232] (on a tripod or 
attached to the trolley, etc.) prior to the administration of any drugs and assessment for the Main Study.  
• Make sure the subject is in view of the NCM camera a nd start recording.   
• If non -contact [CONTACT_231029], the Main Study will continue without 
stoppi[INVESTIGATOR_230949] -part.  
• Exact placement and distance of the cameras should be documented on the paper CRF.  

Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 77 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Raw non -contact  [CONTACT_231030].  
 
Analysis  
The collected data from a pulse oximeter, capnography, and depth -sensing camera equipment will be 
used to develop a real -time non -contact [CONTACT_15206][INVESTIGATOR_230950]. Data will be analyzed and po st-
processed for this purpose. Additional analysis may be performed as necessary.  
 
  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 78 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  19. Version History  
Version  Summary of Changes  Author(s)/Title  
1.0 Not Applicable, New Document  Julia Katilius, Ph .D./ 
Sr. Clinical Program Manager 
Stephanie Monza, BS, CCRC  
Sr. Clinical Research Specialist  
2.0 • Addition of Pi[INVESTIGATOR_230884]  
• Changed TES assessment from one 
stimulation to 4 graduated stimulations  
• Added UADE reporting requirements to 
address GAP identified in versioning  
• Clarification of Adverse Events 
collection time period  
• Clarification of Anesthesiologists 
permitted to perform MOAA/S 
assessment  
 Stephanie Monza , BS, CCRC  
Sr. Clinical Research Specialist  
3.0 • Change of procedure to increase 
anesthesia until a BIS™  value of 30 is 
reach or per Inv estigator’s discretion  
• Clarification of Statistical Plan  
• Pi[INVESTIGATOR_230951] S Stephanie Monza, BS, CCRC  
Sr. Clinical Research Specialist  
4.0 • Clarification of Pi[INVESTIGATOR_230952]  
• Change of Anesthesia amounts to align 
to anesthesia device delivery amounts  
• Additional step of sevoflurane due to 
incidence of hypotension  
• Addition of use of lidocaine to decrease 
discomfort to subjects  
• Change of timing of TES assessment to ensure adequate sedation  
• Addition of phenylephr ine to prevent 
hypotension  
• Addition of NCM sub -study  Stephanie Monza, BS, CCRC  
Sr. Clinical Research Specialist  
5.0 • Change in administration of 
phenylephrine  to be at the 
investigator’s discretion  Ami Stuart, PhD, MSCI  
Sr. Clinical Research Specialist  
Evaluati on of BIS ™ and Levels of Sedat ion with Common Inhalation Anesthetics 
in Healthy V olunte ers  
Clinical Investigation Plan  
  
MDT19053OLIVER  Version  5.0 Page 79 of 79 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Addition of ondansetron to prevent 
emesis / nausea  administered at the 
investigator’s discretion  
• Update of contact [CONTACT_231031]  
 
  